{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:12:34Z","timestamp":1792717954972,"version":"4.5.0"},"reference-count":289,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,6,8]],"date-time":"2017-06-08T00:00:00Z","timestamp":1496880000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,6,8]],"date-time":"2017-06-08T00:00:00Z","timestamp":1496880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precision Onc"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Reduction-oxidation factor 1-apurinic\/apyrimidinic endonuclease (Ref-1\/APE1) is a critical node in tumor cells, both as a redox regulator of transcription factor activation and as part of the DNA damage response. As a redox signaling protein, Ref-1\/APE1 enhances the transcriptional activity of STAT3, HIF-1\u03b1, nuclear factor kappa B, and other transcription factors to promote growth, migration, and survival in tumor cells as well as inflammation and angiogenesis in the tumor microenvironment. Ref-1\/APE1 is activated in a variety of cancers, including prostate, colon, pancreatic, ovarian, lung and leukemias, leading to increased aggressiveness. Transcription factors downstream of Ref-1\/APE1 are key contributors to many cancers, and Ref-1\/APE1 redox signaling inhibition slows growth and progression in a number of tumor types. Ref-1\/APE1 inhibition is also highly effective when paired with other drugs, including standard-of-care therapies and therapies targeting pathways affected by Ref-1\/APE1 redox signaling. Additionally, Ref-1\/APE1 plays a role in a variety of other indications, such as retinopathy, inflammation, and neuropathy. In this review, we discuss the functional consequences of activation of the Ref-1\/APE1 node in cancer and other diseases, as well as potential therapies targeting Ref-1\/APE1 and related pathways in relevant diseases. APX3330, a novel oral anticancer agent and the first drug to target Ref-1\/APE1 for cancer is entering clinical trials and will be explored in various cancers and other diseases bringing bench discoveries to the clinic.<\/jats:p>","DOI":"10.1038\/s41698-017-0023-0","type":"journal-article","created":{"date-parts":[[2017,5,31]],"date-time":"2017-05-31T14:56:44Z","timestamp":1496242604000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":117,"title":["Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic"],"prefix":"10.1038","volume":"1","author":[{"given":"Fenil","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Logsdon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Messmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill C.","family":"Fehrenbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa L.","family":"Fishel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Kelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,8]]},"reference":[{"key":"23_CR1","doi-asserted-by":"publisher","first-page":"11450","DOI":"10.1073\/pnas.88.24.11450","volume":"88","author":"B Demple","year":"1991","unstructured":"Demple, B., Herman, T. & Chen, D. S. Cloning and expression of APE, the cDNA encoding the major human apurinic endonuclease: definition of a family of DNA repair enzymes. Proc. Natl. Acad. Sci. USA \n                           88, 11450\u201311454 (1991).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"23_CR2","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.mam.2007.04.005","volume":"28","author":"ML Fishel","year":"2007","unstructured":"Fishel, M. L. & Kelley, M. R. The DNA base excision repair protein Ape1\/Ref-1 as a therapeutic and chemopreventive target. Mol. Aspects Med. \n                           28, 375\u2013395 (2007).","journal-title":"Mol. Aspects Med."},{"key":"23_CR3","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.2217\/fon.14.60","volume":"10","author":"MR Kelley","year":"2014","unstructured":"Kelley, M. R., Logsdon, D. & Fishel, M. L. Targeting DNA repair pathways for cancer treatment: what\u2019s new? Future Oncol. \n                           10, 1215\u20131237 (2014).","journal-title":"Future Oncol."},{"key":"23_CR4","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/j.1460-2075.1992.tb05097.x","volume":"11","author":"S Xanthoudakis","year":"1992","unstructured":"Xanthoudakis, S. & Curran, T. Identification and characterization of Ref-1, a nuclear protein that facilitates AP-1 DNA-binding activity. EMBO J. \n                           11, 653\u2013665 (1992).","journal-title":"EMBO J."},{"key":"23_CR5","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1002\/j.1460-2075.1992.tb05411.x","volume":"11","author":"S Xanthoudakis","year":"1992","unstructured":"Xanthoudakis, S., Miao, G., Wang, F., Pan, Y. C. & Curran, T. Redox activation of Fos-Jun DNA binding activity is mediated by a DNA repair enzyme. EMBO J. \n                           11, 3323\u20133335 (1992).","journal-title":"EMBO J."},{"key":"23_CR6","doi-asserted-by":"publisher","first-page":"18289","DOI":"10.1074\/jbc.M212143200","volume":"278","author":"KM Chou","year":"2003","unstructured":"Chou, K. M. & Cheng, Y. C. The exonuclease activity of human apurinic\/apyrimidinic endonuclease (APE1). Biochemical properties and inhibition by the natural dinucleotide Gp4G. J. Biol. Chem. \n                           278, 18289\u201318296 (2003).","journal-title":"J. Biol. Chem."},{"key":"23_CR7","doi-asserted-by":"publisher","first-page":"36242","DOI":"10.1074\/jbc.M306065200","volume":"278","author":"D Wong","year":"2003","unstructured":"Wong, D., DeMott, M. S. & Demple, B. Modulation of the 3\u2019-->5\u2019-exonuclease activity of human apurinic endonuclease (Ape1) by its 5\u2019-incised abasic DNA product. J. Biol. Chem. \n                           278, 36242\u201336249 (2003).","journal-title":"J. Biol. Chem."},{"key":"23_CR8","doi-asserted-by":"publisher","first-page":"E3071","DOI":"10.1073\/pnas.1305281110","volume":"110","author":"A Mazouzi","year":"2013","unstructured":"Mazouzi, A. et al. Insight into mechanisms of 3\u2019-5\u2019 exonuclease activity and removal of bulky 8,5\u2019-cyclopurine adducts by apurinic\/apyrimidinic endonucleases. Proc. Natl. Acad. Sci. USA \n                           110, E3071\u20133080 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"23_CR9","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1096\/fasebj.26.1_supplement.537.1","volume":"26","author":"L Lirussi","year":"2012","unstructured":"Lirussi, L. et al. NPM1 and APE1: nucleolar teamwork in controlling base excision DNA repair. FASEB J. \n                           26, 537 (2012). 531.","journal-title":"FASEB J."},{"key":"23_CR10","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1128\/MCB.01337-08","volume":"29","author":"C Vascotto","year":"2009","unstructured":"Vascotto, C. et al. APE1\/Ref-1 interacts with NPM1 within nucleoli and plays a role in the rRNA quality control process. Mol. Cell Biol. \n                           29, 1834\u20131854 (2009).","journal-title":"Mol. Cell Biol."},{"key":"23_CR11","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.dnarep.2007.09.008","volume":"7","author":"ML Fishel","year":"2008","unstructured":"Fishel, M. L. et al. Knockdown of the DNA repair and redox signaling protein Ape1\/Ref-1 blocks ovarian cancer cell and tumor growth. DNA Repair (Amst.) \n                           7, 177\u2013186 (2008).","journal-title":"DNA Repair (Amst.)"},{"key":"23_CR12","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.mrfmmm.2008.04.008","volume":"643","author":"MM Georgiadis","year":"2008","unstructured":"Georgiadis, M. M. et al. Evolution of the redox function in mammalian apurinic\/apyrimidinic endonuclease. Mutat. Res. \n                           643, 54\u201363 (2008).","journal-title":"Mutat. Res."},{"key":"23_CR13","doi-asserted-by":"publisher","first-page":"e47462","DOI":"10.1371\/journal.pone.0047462","volume":"7","author":"AA Cardoso","year":"2012","unstructured":"Cardoso, A. A. et al. APE1\/Ref-1 regulates STAT3 transcriptional activity and APE1\/Ref-1-STAT3 dual-targeting effectively inhibits pancreatic cancer cell survival. PLoS One \n                           7, e47462 (2012).","journal-title":"PLoS One"},{"key":"23_CR14","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1158\/1535-7163.MCT-16-0253","volume":"15","author":"DP Logsdon","year":"2016","unstructured":"Logsdon, D. P. et al. Regulation of HIF1alpha under Hypoxia by APE1\/Ref-1 Impacts CA9 expression: Dual targeting in patient-derived 3D pancreatic cancer models. Mol. Cancer Ther. \n                           15, 2722\u20132732 (2016).","journal-title":"Mol. Cancer Ther."},{"key":"23_CR15","doi-asserted-by":"publisher","first-page":"44548","DOI":"10.1074\/jbc.M202970200","volume":"277","author":"T Nishi","year":"2002","unstructured":"Nishi, T. et al. Spatial redox regulation of a critical cysteine residue of NF-kappa B in vivo. J. Biol. Chem. \n                           277, 44548\u201344556 (2002).","journal-title":"J. Biol. Chem."},{"key":"23_CR16","doi-asserted-by":"publisher","first-page":"14548","DOI":"10.1073\/pnas.212319799","volume":"99","author":"YR Seo","year":"2002","unstructured":"Seo, Y. R., Kelley, M. R. & Smith, M. L. Selenomethionine regulation of p53 by a ref1-dependent redox mechanism. Proc. Natl. Acad. Sci. USA \n                           99, 14548\u201314553 (2002).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"23_CR17","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1074\/jbc.M114.621995","volume":"290","author":"ML Fishel","year":"2015","unstructured":"Fishel, M. L. et al. Apurinic\/apyrimidinic endonuclease\/redox factor-1 (APE1\/Ref-1) redox function negatively regulates NRF2. J. Biol. Chem. \n                           290, 3057\u20133068 (2015).","journal-title":"J. Biol. Chem."},{"key":"23_CR18","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1158\/1535-7163.MCT-11-0107","volume":"10","author":"ML Fishel","year":"2011","unstructured":"Fishel, M. L. et al. Impact of APE1\/Ref-1 redox inhibition on pancreatic tumor growth. Mol. Cancer Ther. \n                           10, 1698\u20131708 (2011).","journal-title":"Mol. Cancer Ther."},{"key":"23_CR19","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S0921-8777(00)00046-X","volume":"461","author":"AR Evans","year":"2000","unstructured":"Evans, A. R., Limp-Foster, M. & Kelley, M. R. Going APE over ref-1. Mutat. Res. \n                           461, 83\u2013108 (2000).","journal-title":"Mutat. Res."},{"key":"23_CR20","doi-asserted-by":"publisher","first-page":"36","DOI":"10.2174\/1874467211205010036","volume":"5","author":"MR Kelley","year":"2012","unstructured":"Kelley, M. R., Georgiadis, M. M. & Fishel, M. L. APE1\/Ref-1 role in redox signaling: translational applications of targeting the redox function of the DNA repair\/redox protein APE1\/Ref-1. Curr. Mol. Pharmacol. \n                           5, 36\u201353 (2012).","journal-title":"Curr. Mol. Pharmacol."},{"key":"23_CR21","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1021\/bi201034z","volume":"51","author":"M Luo","year":"2012","unstructured":"Luo, M. et al. Characterization of the redox activity and disulfide bond formation in apurinic\/apyrimidinic endonuclease. Biochemistry \n                           51, 695\u2013705 (2012).","journal-title":"Biochemistry"},{"key":"23_CR22","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1021\/bi400179m","volume":"52","author":"J Zhang","year":"2013","unstructured":"Zhang, J. et al. Inhibition of apurinic\/apyrimidinic endonuclease I\u2019s redox activity revisited. Biochemistry \n                           52, 2955\u20132966 (2013).","journal-title":"Biochemistry"},{"key":"23_CR23","doi-asserted-by":"publisher","first-page":"8222","DOI":"10.1158\/0008-5472.CAN-10-0894","volume":"70","author":"L Li","year":"2010","unstructured":"Li, L., Cheung, S. H., Evans, E. L. & Shaw, P. E. Modulation of gene expression and tumor cell growth by redox modification of STAT3. Cancer Res. \n                           70, 8222\u20138232 (2010).","journal-title":"Cancer Res."},{"key":"23_CR24","doi-asserted-by":"publisher","first-page":"4618","DOI":"10.1074\/jbc.275.7.4618","volume":"275","author":"D Lando","year":"2000","unstructured":"Lando, D., Pongratz, I., Poellinger, L. & Whitelaw, M. L. A redox mechanism controls differential DNA binding activities of hypoxia-inducible factor (HIF) 1alpha and the HIF-like factor. J. Biol. Chem. \n                           275, 4618\u20134627 (2000).","journal-title":"J. Biol. Chem."},{"key":"23_CR25","doi-asserted-by":"publisher","first-page":"885","DOI":"10.3109\/07357907.2010.512816","volume":"28","author":"Y Jiang","year":"2010","unstructured":"Jiang, Y., Zhou, S., Sandusky, G. E., Kelley, M. R. & Fishel, M. L. Reduced expression of DNA repair and redox signaling protein APE1\/Ref-1 impairs human pancreatic cancer cell survival, proliferation, and cell cycle progression. Cancer Invest. \n                           28, 885\u2013895 (2010).","journal-title":"Cancer Invest."},{"key":"23_CR26","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3389\/fnut.2015.00010","volume":"2","author":"G Sharbeen","year":"2015","unstructured":"Sharbeen, G., McCarroll, J., Goldstein, D. & Phillips, P. A. Exploiting base excision repair to improve therapeutic approaches for pancreatic cancer. Front. Nutr. \n                           2, 10 (2015).","journal-title":"Front. Nutr."},{"key":"23_CR27","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.exphem.2010.08.011","volume":"38","author":"ML Fishel","year":"2010","unstructured":"Fishel, M. L., Colvin, E. S., Luo, M., Kelley, M. R. & Robertson, K. A. Inhibition of the redox function of APE1\/Ref-1 in myeloid leukemia cell lines results in a hypersensitive response to retinoic acid-induced differentiation and apoptosis. Exp. Hematol. \n                           38, 1178\u20131188 (2010).","journal-title":"Exp. Hematol."},{"key":"23_CR28","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1021\/bi101248s","volume":"50","author":"DG Su","year":"2011","unstructured":"Su, D. G. et al. Interactions of APE1 with a redox inhibitor: Evidence for an alternate conformation of the enzyme. Biochemistry \n                           50, 82\u201392 (2011).","journal-title":"Biochemistry"},{"key":"23_CR29","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1089\/ars.2008.2120","volume":"10","author":"M Luo","year":"2008","unstructured":"Luo, M. et al. Role of the multifunctional DNA repair and redox signaling protein Ape1\/Ref-1 in cancer and endothelial cells: small-molecule inhibition of the redox function of Ape1. Antioxid. Redox. Signal. \n                           10, 1853\u20131867 (2008).","journal-title":"Antioxid. Redox. Signal."},{"key":"23_CR30","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1158\/1535-7163.MCT-08-0113","volume":"7","author":"GM Zou","year":"2008","unstructured":"Zou, G. M. & Maitra, A. Small-molecule inhibitor of the AP endonuclease 1\/REF-1 E3330 inhibits pancreatic cancer cell growth and migration. Mol. Cancer Ther. \n                           7, 2012\u20132021 (2008).","journal-title":"Mol. Cancer Ther."},{"key":"23_CR31","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.dnarep.2011.06.004","volume":"10","author":"MR Vasko","year":"2011","unstructured":"Vasko, M. R., Guo, C., Thompson, E. L. & Kelley, M. R. The repair function of the multifunctional DNA repair\/redox protein APE1 is neuroprotective after ionizing radiation. DNA Repair (Amst.) \n                           10, 942\u2013952 (2011).","journal-title":"DNA Repair (Amst.)"},{"key":"23_CR32","doi-asserted-by":"crossref","first-page":"525","DOI":"10.31989\/ffhd.v1i12.108","volume":"1","author":"AR Bassiouny","year":"2011","unstructured":"Bassiouny, A. R., Atteya, M. A., El-Rashidy, F. H. & Neenaa, H. M. Curcumin and EGCG suppress apurinic\/apyrimidinic endonuclease 1 and induce complete remission in B-cell non-Hodgkin\u2019s lymphoma patients. Funct. Foods Health Dis. \n                           1, 525\u2013544 (2011).","journal-title":"Funct. Foods Health Dis."},{"key":"23_CR33","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1158\/0008-5472.CAN-06-2147","volume":"67","author":"JJ Raffoul","year":"2007","unstructured":"Raffoul, J. J. et al. Down-regulation of apurinic\/apyrimidinic endonuclease 1\/redox factor-1 expression by soy isoflavones enhances prostate cancer radiotherapy in vitro and in vivo. Cancer Res. \n                           67, 2141\u20132149 (2007).","journal-title":"Cancer Res."},{"key":"23_CR34","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1038\/emm.2014.42","volume":"46","author":"S Thakur","year":"2014","unstructured":"Thakur, S. et al. APE1\/Ref-1 as an emerging therapeutic target for various human diseases: phytochemical modulation of its functions. Exp. Mol. Med. \n                           46, e106 (2014).","journal-title":"Exp. Mol. Med."},{"key":"23_CR35","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1158\/1535-7163.MCT-05-0229","volume":"4","author":"S Yang","year":"2005","unstructured":"Yang, S., Irani, K., Heffron, S. E., Jurnak, F. & Meyskens, F. L. Jr. Alterations in the expression of the apurinic\/apyrimidinic endonuclease-1\/redox factor-1 (APE\/Ref-1) in human melanoma and identification of the therapeutic potential of resveratrol as an APE\/Ref-1 inhibitor. Mol. Cancer Ther. \n                           4, 1923\u20131935 (2005).","journal-title":"Mol. Cancer Ther."},{"key":"23_CR36","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1093\/jn\/132.7.2076","volume":"132","author":"X Gao","year":"2002","unstructured":"Gao, X. et al. Disparate in vitro and in vivo antileukemic effects of resveratrol, a natural polyphenolic compound found in grapes. J. Nutr. \n                           132, 2076\u20132081 (2002).","journal-title":"J. Nutr."},{"key":"23_CR37","doi-asserted-by":"publisher","first-page":"837042","DOI":"10.1155\/2015\/837042","volume":"2015","author":"J Gambini","year":"2015","unstructured":"Gambini, J. et al. Properties of resveratrol: In vitro and in vivo studies about metabolism, bioavailability, and biological effects in animal models and humans. Oxid. Med. Cell. Longev. \n                           2015, 837042 (2015).","journal-title":"Oxid. Med. Cell. Longev."},{"key":"23_CR38","doi-asserted-by":"publisher","first-page":"R209","DOI":"10.1530\/ERC-13-0171","volume":"21","author":"LG Carter","year":"2014","unstructured":"Carter, L. G., D\u2019Orazio, J. A. & Pearson, K. J. Resveratrol and cancer: focus on in vivo evidence. Endocr. Relat. Cancer \n                           21, R209\u2013R225 (2014).","journal-title":"Endocr. Relat. Cancer"},{"key":"23_CR39","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nrd2060","volume":"5","author":"JA Baur","year":"2006","unstructured":"Baur, J. A. & Sinclair, D. A. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov. \n                           5, 493\u2013506 (2006).","journal-title":"Nat. Rev. Drug Discov."},{"key":"23_CR40","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1021\/cb500086e","volume":"9","author":"HI Ingolfsson","year":"2014","unstructured":"Ingolfsson, H. I. et al. Phytochemicals perturb membranes and promiscuously alter protein function. ACS Chem. Biol. \n                           9, 1788\u20131798 (2014).","journal-title":"ACS Chem. Biol."},{"key":"23_CR41","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/513481a","volume":"513","author":"J Baell","year":"2014","unstructured":"Baell, J. & Walters, M. A. Chemistry: chemical con artists foil drug discovery. Nature \n                           513, 481\u2013483 (2014).","journal-title":"Nature"},{"key":"23_CR42","first-page":"2093","volume":"19","author":"KI Priyadarsini","year":"2013","unstructured":"Priyadarsini, K. I. Chemical and structural features influencing the biological activity of curcumin. Curr. Pharm. Des. \n                           19, 2093\u20132100 (2013).","journal-title":"Curr. Pharm. Des."},{"key":"23_CR43","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/541144a","volume":"541","author":"M Baker","year":"2017","unstructured":"Baker, M. Deceptive curcumin offers cautionary tale for chemists. Nature \n                           541, 144\u2013145 (2017).","journal-title":"Nature"},{"key":"23_CR44","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.immuni.2012.03.013","volume":"36","author":"GR Stark","year":"2012","unstructured":"Stark, G. R. & Darnell, J. E. Jr. The JAK-STAT pathway at twenty. Immunity \n                           36, 503\u2013514 (2012).","journal-title":"Immunity"},{"key":"23_CR45","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1126\/science.8197455","volume":"264","author":"JE Darnell Jr.","year":"1994","unstructured":"Darnell, J. E. Jr., Kerr, I. M. & Stark, G. R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science \n                           264, 1415\u20131421 (1994).","journal-title":"Science"},{"key":"23_CR46","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/nrc3818","volume":"14","author":"H Yu","year":"2014","unstructured":"Yu, H., Lee, H., Herrmann, A., Buettner, R. & Jove, R. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat. Rev. Cancer \n                           14, 736\u2013746 (2014).","journal-title":"Nat. Rev. Cancer"},{"key":"23_CR47","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/nrc2734","volume":"9","author":"H Yu","year":"2009","unstructured":"Yu, H., Pardoll, D. & Jove, R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer \n                           9, 798\u2013809 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"23_CR48","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.ccr.2011.03.002","volume":"19","author":"A Fukuda","year":"2011","unstructured":"Fukuda, A. et al. Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell \n                           19, 441\u2013455 (2011).","journal-title":"Cancer Cell"},{"key":"23_CR49","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell \n                           144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"23_CR50","doi-asserted-by":"publisher","first-page":"11553","DOI":"10.1007\/s13277-016-5098-7","volume":"37","author":"N Kumari","year":"2016","unstructured":"Kumari, N., Dwarakanath, B. S., Das, A. & Bhatt, A. N. Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol. \n                           37, 11553\u201311572 (2016).","journal-title":"Tumour Biol."},{"key":"23_CR51","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/S0016-5085(03)01064-3","volume":"125","author":"A Scholz","year":"2003","unstructured":"Scholz, A. et al. Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer. Gastroenterology \n                           125, 891\u2013905 (2003).","journal-title":"Gastroenterology"},{"key":"23_CR52","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ccr.2011.03.009","volume":"19","author":"M Lesina","year":"2011","unstructured":"Lesina, M. et al. Stat3\/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell \n                           19, 456\u2013469 (2011).","journal-title":"Cancer Cell"},{"key":"23_CR53","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/1756-9966-29-51","volume":"29","author":"C Huang","year":"2010","unstructured":"Huang, C. et al. Effects of IL-6 and AG490 on regulation of Stat3 signaling pathway and invasion of human pancreatic cancer cells in vitro. J. Exp. Clin. Cancer Res. \n                           29, 51 (2010).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"23_CR54","doi-asserted-by":"publisher","first-page":"5819","DOI":"10.1074\/jbc.M111.295964","volume":"287","author":"H Xiong","year":"2012","unstructured":"Xiong, H. et al. Roles of STAT3 and ZEB1 proteins in E-cadherin down-regulation and human colorectal cancer epithelial-mesenchymal transition. J. Biol. Chem. \n                           287, 5819\u20135832 (2012).","journal-title":"J. Biol. Chem."},{"key":"23_CR55","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1093\/carcin\/bgt167","volume":"34","author":"Y Teng","year":"2013","unstructured":"Teng, Y., Ghoshal, P., Ngoka, L., Mei, Y. & Cowell, J. K. Critical role of the WASF3 gene in JAK2\/STAT3 regulation of cancer cell motility. Carcinogenesis \n                           34, 1994\u20131999 (2013).","journal-title":"Carcinogenesis"},{"key":"23_CR56","doi-asserted-by":"publisher","first-page":"17954","DOI":"10.1074\/jbc.M113.475277","volume":"288","author":"N Balanis","year":"2013","unstructured":"Balanis, N. et al. Epithelial to mesenchymal transition promotes breast cancer progression via a fibronectin-dependent STAT3 signaling pathway. J. Biol. Chem. \n                           288, 17954\u201317967 (2013).","journal-title":"J. Biol. Chem."},{"key":"23_CR57","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.drudis.2007.06.003","volume":"12","author":"B Pirard","year":"2007","unstructured":"Pirard, B. Insight into the structural determinants for selective inhibition of matrix metalloproteinases. Drug Discov. Today \n                           12, 640\u2013646 (2007).","journal-title":"Drug Discov. Today"},{"key":"23_CR58","doi-asserted-by":"publisher","first-page":"6139","DOI":"10.1007\/s13277-015-3298-1","volume":"36","author":"K Zhong","year":"2015","unstructured":"Zhong, K., Chen, W., Xiao, N. & Zhao, J. The clinicopathological significance and potential drug target of E-cadherin in NSCLC. Tumour Biol. \n                           36, 6139\u20136148 (2015).","journal-title":"Tumour Biol."},{"key":"23_CR59","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1093\/carcin\/bgm047","volume":"28","author":"M Pennati","year":"2007","unstructured":"Pennati, M., Folini, M. & Zaffaroni, N. Targeting survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis \n                           28, 1133\u20131139 (2007).","journal-title":"Carcinogenesis"},{"key":"23_CR60","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers, A. J. et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. \n                           19, 202\u2013208 (2013).","journal-title":"Nat. Med."},{"key":"23_CR61","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.2174\/092986711796957284","volume":"18","author":"M Zhao","year":"2011","unstructured":"Zhao, M., Jiang, B. & Gao, F. H. Small molecule inhibitors of STAT3 for cancer therapy. Curr. Med. Chem. \n                           18, 4012\u20134018 (2011).","journal-title":"Curr. Med. Chem."},{"key":"23_CR62","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1111\/febs.13285","volume":"282","author":"MS Wake","year":"2015","unstructured":"Wake, M. S. & Watson, C. J. STAT3 the oncogene - still eluding therapy? FEBS J. \n                           282, 2600\u20132611 (2015).","journal-title":"FEBS J."},{"key":"23_CR63","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1021\/acschembio.5b00945","volume":"11","author":"SL Furtek","year":"2016","unstructured":"Furtek, S. L., Backos, D. S., Matheson, C. J. & Reigan, P. Strategies and approaches of targeting STAT3 for cancer treatment. ACS Chem. Biol. \n                           11, 308\u2013318 (2016).","journal-title":"ACS Chem. Biol."},{"key":"23_CR64","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1158\/1535-7163.MCT-15-0003","volume":"15","author":"CC Arpin","year":"2016","unstructured":"Arpin, C. C. et al. Applying small molecule signal transducer and activator of transcription-3 (STAT3) protein inhibitors as pancreatic cancer therapeutics. Mol. Cancer Ther. \n                           15, 794\u2013805 (2016).","journal-title":"Mol. Cancer Ther."},{"key":"23_CR65","doi-asserted-by":"publisher","first-page":"e30820","DOI":"10.1371\/journal.pone.0030820","volume":"7","author":"BD Looyenga","year":"2012","unstructured":"Looyenga, B. D. et al. STAT3 is activated by JAK2 independent of key oncogenic driver mutations in non-small cell lung carcinoma. PLoS One \n                           7, e30820 (2012).","journal-title":"PLoS One"},{"key":"23_CR66","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/nrd3652","volume":"11","author":"RA Mesa","year":"2012","unstructured":"Mesa, R. A., Yasothan, U. & Kirkpatrick, P. Ruxolitinib. Nat. Rev. Drug Discov. \n                           11, 103\u2013104 (2012).","journal-title":"Nat. Rev. Drug Discov."},{"key":"23_CR67","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1056\/NEJMoa1409002","volume":"372","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi, A. M. et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N. Engl. J. Med. \n                           372, 426\u2013435 (2015).","journal-title":"N. Engl. J. Med."},{"key":"23_CR68","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek, S. et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N. Engl. J. Med. \n                           366, 799\u2013807 (2012).","journal-title":"N. Engl. J. Med."},{"key":"23_CR69","doi-asserted-by":"crossref","unstructured":"[Staff]. Ruxolitinib benefits some with pancreatic cancer. Cancer Discov. 5, 1231 (2015).","DOI":"10.1158\/2159-8290.CD-NB2015-142"},{"key":"23_CR70","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jtho.2016.08.140","volume":"12","author":"HA Yu","year":"2017","unstructured":"Yu, H. A. et al. A phase 1\/2 trial of ruxolitinib and erlotinib in patients with EGFR-Mutant lung adenocarcinomas with acquired resistance to Erlotinib. J. Thorac. Oncol. \n                           12, 102\u2013109 (2017).","journal-title":"J. Thorac. Oncol."},{"key":"23_CR71","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.2147\/DDDT.S86438","volume":"9","author":"R Chen","year":"2015","unstructured":"Chen, R. & Chen, B. Siltuximab (CNTO 328): a promising option for human malignancies. Drug Des Devel. Ther. \n                           9, 3455\u20133458 (2015).","journal-title":"Drug Des Devel. Ther."},{"key":"23_CR72","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1093\/annonc\/mdv309","volume":"26","author":"EM Dijkgraaf","year":"2015","unstructured":"Dijkgraaf, E. M. et al. A phase I trial combining carboplatin\/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-alpha2b in patients with recurrent epithelial ovarian cancer. Ann. Oncol. \n                           26, 2141\u20132149 (2015).","journal-title":"Ann. Oncol."},{"key":"23_CR73","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1038\/bjc.2016.327","volume":"115","author":"Y Matsuoka","year":"2016","unstructured":"Matsuoka, Y. et al. IL-6 controls resistance to radiation by suppressing oxidative stress via the Nrf2-antioxidant pathway in oral squamous cell carcinoma. Br. J. Cancer \n                           115, 1234\u20131244 (2016).","journal-title":"Br. J. Cancer"},{"key":"23_CR74","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1158\/1538-7445.AM2014-953","volume":"74","author":"D Genini","year":"2014","unstructured":"Genini, D. et al. Abstract 953: Novel inhibitors of signal transducer and activator of transcription 3 (STAT3) show potent activity in cell cultures and tumor xenografts. Cancer Res. \n                           74, 953 (2014).","journal-title":"Cancer Res."},{"key":"23_CR75","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1080\/13543784.2016.1195807","volume":"25","author":"C Cafferkey","year":"2016","unstructured":"Cafferkey, C. & Chau, I. Novel STAT 3 inhibitors for treating gastric cancer. Expert Opin. Investig. Drugs \n                           25, 1023\u20131031 (2016).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"23_CR76","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.canlet.2013.02.010","volume":"335","author":"MJ Kim","year":"2013","unstructured":"Kim, M. J. et al. OPB-31121, a novel small molecular inhibitor, disrupts the JAK2\/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells. Cancer Lett. \n                           335, 145\u2013152 (2013).","journal-title":"Cancer Lett."},{"key":"23_CR77","doi-asserted-by":"publisher","first-page":"607","DOI":"10.4143\/crt.2014.249","volume":"47","author":"DY Oh","year":"2015","unstructured":"Oh, D. Y. et al. Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors. Cancer Res. Treat. \n                           47, 607\u2013615 (2015).","journal-title":"Cancer Res. Treat."},{"key":"23_CR78","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00280-014-2480-2","volume":"74","author":"JC Bendell","year":"2014","unstructured":"Bendell, J. C. et al. Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors. Cancer Chemother. Pharmacol. \n                           74, 125\u2013130 (2014).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"23_CR79","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/cas.12683","volume":"106","author":"M Ogura","year":"2015","unstructured":"Ogura, M. et al. Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed\/refractory hematological malignancies. Cancer Sci. \n                           106, 896\u2013901 (2015).","journal-title":"Cancer Sci."},{"key":"23_CR80","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1093\/annonc\/mdv026","volume":"26","author":"AL Wong","year":"2015","unstructured":"Wong, A. L. et al. Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies. Ann. Oncol. \n                           26, 998\u20131005 (2015).","journal-title":"Ann. Oncol."},{"key":"23_CR81","doi-asserted-by":"crossref","unstructured":"Zhang, S. et al. Serum APE1 as a predictive marker for platinum-based chemotherapy of non-small cell lung cancer patients. Oncotarget (2016).","DOI":"10.18632\/oncotarget.13030"},{"key":"23_CR82","doi-asserted-by":"crossref","unstructured":"Bekaii-Saab, T. & El-Rayes, B. Identifying and targeting cancer stem cells in the treatment of gastric cancer. Cancer (2017).","DOI":"10.1002\/cncr.30538"},{"key":"23_CR83","unstructured":"ClinicalTrials.gov. A study of napabucasin (BBI-608) in combination with FOLFIRI in adult patients with previously treated metastatic colorectal cancer (CanStem303C). \n                           https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02753127. (2017)."},{"key":"23_CR84","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.bbrc.2004.08.014","volume":"322","author":"L Li","year":"2004","unstructured":"Li, L. & Shaw, P. E. A STAT3 dimer formed by inter-chain disulphide bridging during oxidative stress. Biochem. Biophys. Res. Commun. \n                           322, 1005\u20131011 (2004).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"23_CR85","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1210\/me.2009-0319","volume":"24","author":"S Ray","year":"2010","unstructured":"Ray, S., Lee, C., Hou, T., Bhakat, K. K. & Brasier, A. R. Regulation of signal transducer and activator of transcription 3 enhanceosome formation by apurinic\/apyrimidinic endonuclease 1 in hepatic acute phase response. Mol. Endocrinol. \n                           24, 391\u2013401 (2010).","journal-title":"Mol. Endocrinol."},{"key":"23_CR86","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/nchembio.1695","volume":"11","author":"MC Sobotta","year":"2015","unstructured":"Sobotta, M. C. et al. Peroxiredoxin-2 and STAT3 form a redox relay for H2O2 signaling. Nat. Chem. Biol. \n                           11, 64\u201370 (2015).","journal-title":"Nat. Chem. Biol."},{"key":"23_CR87","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nrc2293","volume":"8","author":"DCSurvivin Altieri","year":"2008","unstructured":"Altieri, D. C. Survivin cancer networks and pathway-directed drug discovery. Nat. Rev. Cancer \n                           8, 61\u201370 (2008).","journal-title":"Nat. Rev. Cancer"},{"key":"23_CR88","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.ctrv.2013.02.002","volume":"39","author":"MS Coumar","year":"2013","unstructured":"Coumar, M. S., Tsai, F. Y., Kanwar, J. R., Sarvagalla, S. & Cheung, C. H. Treat cancers by targeting survivin: just a dream or future reality? Cancer Treat. Rev. \n                           39, 802\u2013811 (2013).","journal-title":"Cancer Treat. Rev."},{"key":"23_CR89","doi-asserted-by":"publisher","first-page":"5552","DOI":"10.1038\/sj.onc.1208719","volume":"24","author":"Q Xu","year":"2005","unstructured":"Xu, Q. et al. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene \n                           24, 5552\u20135560 (2005).","journal-title":"Oncogene"},{"key":"23_CR90","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1158\/1541-7786.MCR-14-0182","volume":"13","author":"E Rad","year":"2015","unstructured":"Rad, E., Dodd, K., Thomas, L., Upadhyaya, M. & Tee, A. STAT3 and HIF1alpha signaling drives oncogenic cellular phenotypes in malignant peripheral nerve sheath tumors. Mol. Cancer Res. \n                           13, 1149\u20131160 (2015).","journal-title":"Mol. Cancer Res."},{"key":"23_CR91","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1038\/onc.2013.115","volume":"33","author":"MR Pawlus","year":"2014","unstructured":"Pawlus, M. R., Wang, L. & Hu, C. J. STAT3 and HIF1alpha cooperatively activate HIF1 target genes in MDA-MB-231 and RCC4 cells. Oncogene \n                           33, 1670\u20131679 (2014).","journal-title":"Oncogene"},{"key":"23_CR92","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nrc3204","volume":"12","author":"ND Perkins","year":"2012","unstructured":"Perkins, N. D. The diverse and complex roles of NF-\u03baB subunits in cancer. Nat. Rev. Cancer \n                           12, 121\u2013132 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"23_CR93","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1038\/embor.2009.243","volume":"10","author":"J Bollrath","year":"2009","unstructured":"Bollrath, J. & Greten, F. R. IKK\/NF-kappaB and STAT3 pathways: central signalling hubs in inflammation-mediated tumour promotion and metastasis. EMBO Rep. \n                           10, 1314\u20131319 (2009).","journal-title":"EMBO Rep."},{"key":"23_CR94","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cytogfr.2009.11.005","volume":"21","author":"SI Grivennikov","year":"2010","unstructured":"Grivennikov, S. I. & Karin, M. Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev. \n                           21, 11\u201319 (2010).","journal-title":"Cytokine Growth Factor Rev."},{"key":"23_CR95","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/1476-4598-12-86","volume":"12","author":"B Hoesel","year":"2013","unstructured":"Hoesel, B. & Schmid, J. A. The complexity of NF-\u03baB signaling in inflammation and cancer. Mol. Cancer \n                           12, 86 (2013).","journal-title":"Mol. Cancer"},{"key":"23_CR96","doi-asserted-by":"publisher","first-page":"30082","DOI":"10.1074\/jbc.M114.591719","volume":"289","author":"M Snyder","year":"2014","unstructured":"Snyder, M., Huang, J., Huang, X.-Y. & Zhang, J. J. A signal transducer and activator of transcription 3\u00b7nuclear factor \u03baB (Stat3\u00b7NF\u03baB) complex is necessary for the expression of fascin in metastatic breast cancer cells in response to interleukin (IL)-6 and tumor necrosis factor (TNF)-\u03b1. J. Biol. Chem. \n                           289, 30082\u201330089 (2014).","journal-title":"J. Biol. Chem."},{"key":"23_CR97","doi-asserted-by":"publisher","first-page":"21197","DOI":"10.1074\/jbc.M113.484576","volume":"288","author":"S Arora","year":"2013","unstructured":"Arora, S. et al. An undesired effect of chemotherapy: gemcitabine promotes pancreatic cancer cell invasiveness through reactive oxygen species-dependent, nuclear factor kappaB- and hypoxia-inducible factor 1alpha-mediated up-regulation of CXCR4. J. Biol. Chem. \n                           288, 21197\u201321207 (2013).","journal-title":"J. Biol. Chem."},{"key":"23_CR98","doi-asserted-by":"publisher","first-page":"e1065","DOI":"10.1038\/cddis.2014.38","volume":"5","author":"R Blum","year":"2014","unstructured":"Blum, R. & Kloog, Y. Metabolism addiction in pancreatic cancer. Cell Death Dis. \n                           5, e1065 (2014).","journal-title":"Cell Death Dis."},{"key":"23_CR99","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1158\/0008-5472.CAN-14-2040","volume":"75","author":"T Zhao","year":"2015","unstructured":"Zhao, T. et al. LASP1 is a HIF1alpha target gene critical for metastasis of pancreatic cancer. Cancer Res. \n                           75, 111\u2013119 (2015).","journal-title":"Cancer Res."},{"key":"23_CR100","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1126\/science.1059817","volume":"292","author":"M Ivan","year":"2001","unstructured":"Ivan, M. et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science \n                           292, 464\u2013468 (2001).","journal-title":"Science"},{"key":"23_CR101","doi-asserted-by":"publisher","first-page":"e190","DOI":"10.1038\/oncsis.2015.50","volume":"5","author":"KL Eales","year":"2016","unstructured":"Eales, K. L., Hollinshead, K. E. & Tennant, D. A. Hypoxia and metabolic adaptation of cancer cells. Oncogenesis \n                           5, e190 (2016).","journal-title":"Oncogenesis"},{"key":"23_CR102","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/35017054","volume":"2","author":"M Ohh","year":"2000","unstructured":"Ohh, M. et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat. Cell Biol. \n                           2, 423\u2013427 (2000).","journal-title":"Nat. Cell Biol."},{"key":"23_CR103","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.apsb.2015.05.007","volume":"5","author":"GN Masoud","year":"2015","unstructured":"Masoud, G. N. & Li, W. HIF-1 pathway: role, regulation and intervention for cancer therapy. Acta Pharm. Sin. B \n                           5, 378\u2013389 (2015).","journal-title":"Acta Pharm. Sin. B"},{"key":"23_CR104","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1126\/science.1073440","volume":"296","author":"JH Min","year":"2002","unstructured":"Min, J. H. et al. Structure of an HIF-1alpha -pVHL complex: hydroxyproline recognition in signaling. Science \n                           296, 1886\u20131889 (2002).","journal-title":"Science"},{"key":"23_CR105","doi-asserted-by":"publisher","first-page":"5491","DOI":"10.1158\/0008-5472.CAN-16-0473","volume":"76","author":"EM Wallace","year":"2016","unstructured":"Wallace, E. M. et al. A small-molecule antagonist of HIF2alpha is efficacious in preclinical models of renal cell Carcinoma. Cancer Res. \n                           76, 5491\u20135500 (2016).","journal-title":"Cancer Res."},{"key":"23_CR106","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.mrfmmm.2015.06.010","volume":"779","author":"H-S Kim","year":"2015","unstructured":"Kim, H.-S. et al. APE1, the DNA base excision repair protein, regulates the removal of platinum adducts in sensory neuronal cultures by NER. Mutat. Res. \n                           779, 96\u2013104 (2015).","journal-title":"Mutat. Res."},{"key":"23_CR107","doi-asserted-by":"publisher","first-page":"20551","DOI":"10.3390\/molecules201119717","volume":"20","author":"SY Kim","year":"2015","unstructured":"Kim, S. Y. & Yang, E. G. Recent advances in developing inhibitors for hypoxia-inducible factor prolyl hydroxylases and their therapeutic implications. Molecules \n                           20, 20551\u201320568 (2015).","journal-title":"Molecules"},{"key":"23_CR108","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/nrc2501","volume":"8","author":"BG Wouters","year":"2008","unstructured":"Wouters, B. G. & Koritzinsky, M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat. Rev. Cancer \n                           8, 851\u2013864 (2008).","journal-title":"Nat. Rev. Cancer"},{"key":"23_CR109","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1158\/1078-0432.CCR-09-1314","volume":"16","author":"PJ Houghton","year":"2010","unstructured":"Houghton, P. J. Everolimus. Clin. Cancer Res. \n                           16, 1368\u20131372 (2010).","journal-title":"Clin. Cancer Res."},{"key":"23_CR110","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nrc3800","volume":"14","author":"M Wang","year":"2014","unstructured":"Wang, M. & Kaufman, R. J. The impact of the endoplasmic reticulum protein-folding environment on cancer development. Nat. Rev. Cancer \n                           14, 581\u2013597 (2014).","journal-title":"Nat. Rev. Cancer"},{"key":"23_CR111","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1074\/jbc.M113.507194","volume":"289","author":"ER Pereira","year":"2014","unstructured":"Pereira, E. R., Frudd, K., Awad, W. & Hendershot, L. M. Endoplasmic reticulum (ER) stress and hypoxia response pathways interact to potentiate hypoxia-inducible factor 1 (HIF-1) transcriptional activity on targets like vascular endothelial growth factor (VEGF). J. Biol. Chem. \n                           289, 3352\u20133364 (2014).","journal-title":"J. Biol. Chem."},{"key":"23_CR112","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/nature13119","volume":"508","author":"X Chen","year":"2014","unstructured":"Chen, X. et al. XBP1 promotes triple-negative breast cancer by controlling the HIF1alpha pathway. Nature \n                           508, 103\u2013107 (2014).","journal-title":"Nature"},{"key":"23_CR113","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1158\/1535-7163.MCT-16-0167","volume":"15","author":"C Gstalder","year":"2016","unstructured":"Gstalder, C., Ader, I. & Cuvillier, O. FTY720 (fingolimod) inhibits HIF1 and HIF2 signaling, promotes vascular remodeling, and chemosensitizes in renal cell carcinoma animal model. Mol. Cancer Ther. \n                           15, 2465\u20132474 (2016).","journal-title":"Mol. Cancer Ther."},{"key":"23_CR114","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1016\/j.transproceed.2008.03.150","volume":"40","author":"Y Shen","year":"2008","unstructured":"Shen, Y. et al. Antiproliferative and overadditive effects of rapamycin and FTY720 in pancreatic cancer cells in vitro. Transplant. Proc. \n                           40, 1727\u20131733 (2008).","journal-title":"Transplant. Proc."},{"key":"23_CR115","doi-asserted-by":"publisher","first-page":"G176","DOI":"10.1152\/ajpgi.00053.2011","volume":"302","author":"Y Zhu","year":"2012","unstructured":"Zhu, Y. et al. Systemic administration of anti-NGF increases A-type potassium currents and decreases pancreatic nociceptor excitability in a rat model of chronic pancreatitis. Am. J. Physiol. Gastrointest. Liver Physiol. \n                           302, G176\u2013G181 (2012).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"23_CR116","doi-asserted-by":"publisher","first-page":"3729","DOI":"10.1158\/1535-7163.MCT-08-0074","volume":"7","author":"SH Li","year":"2008","unstructured":"Li, S. H. et al. A novel mode of action of YC-1 in HIF inhibition: stimulation of FIH-dependent p300 dissociation from HIF-1{alpha}. Mol. Cancer Ther. \n                           7, 3729\u20133738 (2008).","journal-title":"Mol. Cancer Ther."},{"key":"23_CR117","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/nrd.2015.17","volume":"15","author":"N Ferrara","year":"2016","unstructured":"Ferrara, N. & Adamis, A. P. Ten years of anti-vascular endothelial growth factor therapy. Nat. Rev. Drug Discov. \n                           15, 385\u2013403 (2016).","journal-title":"Nat. Rev. Drug Discov."},{"key":"23_CR118","doi-asserted-by":"publisher","first-page":"164","DOI":"10.2174\/1389450115666141120120145","volume":"16","author":"R Iacovelli","year":"2015","unstructured":"Iacovelli, R. et al. Inhibition of the VEGF\/VEGFR pathway improves survival in advanced kidney cancer: a systematic review and meta-analysis. Curr. Drug Targets \n                           16, 164\u2013170 (2015).","journal-title":"Curr. Drug Targets"},{"key":"23_CR119","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1517\/14728222.2011.641951","volume":"16","author":"MJ Waldner","year":"2012","unstructured":"Waldner, M. J. & Neurath, M. F. Targeting the VEGF signaling pathway in cancer therapy. Expert Opin. Ther. Targets \n                           16, 5\u201313 (2012).","journal-title":"Expert Opin. Ther. Targets"},{"key":"23_CR120","first-page":"519","volume":"7","author":"G Lupo","year":"2016","unstructured":"Lupo, G. et al. Anti-angiogenic therapy in cancer: downsides and new pivots for precision medicine. Front. Pharmacol. \n                           7, 519 (2016).","journal-title":"Front. Pharmacol."},{"key":"23_CR121","doi-asserted-by":"crossref","first-page":"84","DOI":"10.18632\/oncotarget.422","volume":"3","author":"PC McDonald","year":"2012","unstructured":"McDonald, P. C., Winum, J. Y., Supuran, C. T. & Dedhar, S. Recent developments in targeting carbonic anhydrase IX for cancer therapeutics. Oncotarget \n                           3, 84\u201397 (2012).","journal-title":"Oncotarget"},{"key":"23_CR122","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/978-94-007-7359-2_10","volume":"75","author":"E Oosterwijk","year":"2014","unstructured":"Oosterwijk, E. Carbonic anhydrase expression in kidney and renal cancer: implications for diagnosis and treatment. Subcell. Biochem. \n                           75, 181\u2013198 (2014).","journal-title":"Subcell. Biochem."},{"key":"23_CR123","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3109\/14756366.2015.1122001","volume":"31","author":"CT Supuran","year":"2016","unstructured":"Supuran, C. T. How many carbonic anhydrase inhibition mechanisms exist? J. Enzyme Inhib. Med. Chem. \n                           31, 345\u2013360 (2016).","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"23_CR124","doi-asserted-by":"crossref","unstructured":"Parks, S. K. & Pouyssegur, J. Targeting pH regulating proteins for cancer therapy - Progress and Limitations. Semin. Cancer Biol. (2017).","DOI":"10.1016\/j.semcancer.2017.01.007"},{"key":"23_CR125","doi-asserted-by":"publisher","first-page":"400","DOI":"10.3389\/fphys.2013.00400","volume":"4","author":"O Sedlakova","year":"2014","unstructured":"Sedlakova, O. et al. Carbonic anhydrase IX, a hypoxia-induced catalytic component of the pH regulating machinery in tumors. Front. Physiol. \n                           4, 400 (2014).","journal-title":"Front. Physiol."},{"key":"23_CR126","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1158\/1078-0432.CCR-11-1877","volume":"18","author":"A McIntyre","year":"2012","unstructured":"McIntyre, A. et al. Carbonic anhydrase IX promotes tumor growth and necrosis in vivo and inhibition enhances anti-VEGF therapy. Clin. Cancer Res. \n                           18, 3100\u20133111 (2012).","journal-title":"Clin. Cancer Res."},{"key":"23_CR127","doi-asserted-by":"publisher","first-page":"20299","DOI":"10.1074\/jbc.M109.006478","volume":"284","author":"P Swietach","year":"2009","unstructured":"Swietach, P., Patiar, S., Supuran, C. T., Harris, A. L. & Vaughan-Jones, R. D. The role of carbonic anhydrase 9 in regulating extracellular and intracellular ph in three-dimensional tumor cell growths. J. Biol. Chem. \n                           284, 20299\u201320310 (2009).","journal-title":"J. Biol. Chem."},{"key":"23_CR128","first-page":"162","volume":"1795","author":"S Kaluz","year":"2009","unstructured":"Kaluz, S., Kaluzova, M., Liao, S. Y., Lerman, M. & Stanbridge, E. J. Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: a one transcription factor (HIF-1) show? Biochim. Biophys. Acta \n                           1795, 162\u2013172 (2009).","journal-title":"Biochim. Biophys. Acta"},{"key":"23_CR129","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1517\/17460441.2015.1038235","volume":"10","author":"CT Supuran","year":"2015","unstructured":"Supuran, C. T. & Winum, J. Y. Designing carbonic anhydrase inhibitors for the treatment of breast cancer. Expert Opin. Drug Discov. \n                           10, 591\u2013597 (2015).","journal-title":"Expert Opin. Drug Discov."},{"key":"23_CR130","unstructured":"ClinicalTrials.gov. Safety study of SLC-0111 in subjects with advanced solid tumours. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02215850. (2016)."},{"key":"23_CR131","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1080\/17460441.2017.1253677","volume":"12","author":"CT Supuran","year":"2017","unstructured":"Supuran, C. T. Advances in structure-based drug discovery of carbonic anhydrase inhibitors. Expert Opin. Drug Discov. \n                           12, 61\u201388 (2017).","journal-title":"Expert Opin. Drug Discov."},{"key":"23_CR132","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1158\/0008-5472.CAN-15-1862","volume":"76","author":"A McIntyre","year":"2016","unstructured":"McIntyre, A. et al. Disrupting hypoxia-induced bicarbonate transport acidifies tumor cells and suppresses tumor growth. Cancer Res. \n                           76, 3744\u20133755 (2016).","journal-title":"Cancer Res."},{"key":"23_CR133","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nrd2781","volume":"8","author":"V Baud","year":"2009","unstructured":"Baud, V. & Karin, M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat. Rev. Drug Discov. \n                           8, 33\u201340 (2009).","journal-title":"Nat. Rev. Drug Discov."},{"key":"23_CR134","doi-asserted-by":"publisher","first-page":"6817","DOI":"10.1038\/sj.onc.1209942","volume":"25","author":"DS Basseres","year":"2006","unstructured":"Basseres, D. S. & Baldwin, A. S. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene \n                           25, 6817\u20136830 (2006).","journal-title":"Oncogene"},{"key":"23_CR135","first-page":"152","volume":"1846","author":"D Dibra","year":"2014","unstructured":"Dibra, D., Mishra, L. & Li, S. Molecular mechanisms of oncogene-induced inflammation and inflammation-sustained oncogene activation in gastrointestinal tumors: An underappreciated symbiotic relationship. Biochim. Biophys. Acta \n                           1846, 152\u2013160 (2014).","journal-title":"Biochim. Biophys. Acta"},{"key":"23_CR136","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1177\/107327480000700504","volume":"7","author":"D Coppola","year":"2000","unstructured":"Coppola, D. Molecular prognostic markers in pancreatic cancer. Cancer Control \n                           7, 421\u2013427 (2000).","journal-title":"Cancer Control"},{"key":"23_CR137","doi-asserted-by":"publisher","first-page":"e53676","DOI":"10.1371\/journal.pone.0053676","volume":"8","author":"H Doppler","year":"2013","unstructured":"Doppler, H., Liou, G. Y. & Storz, P. Downregulation of TRAF2 mediates NIK-induced pancreatic cancer cell proliferation and tumorigenicity. PLoS One \n                           8, e53676 (2013).","journal-title":"PLoS One"},{"key":"23_CR138","doi-asserted-by":"publisher","first-page":"40924","DOI":"10.1074\/jbc.M112.405837","volume":"287","author":"I Bauer","year":"2012","unstructured":"Bauer, I. et al. The NAD+-dependent histone deacetylase SIRT6 promotes cytokine production and migration in pancreatic cancer cells by regulating Ca2+ responses. J. Biol. Chem. \n                           287, 40924\u201340937 (2012).","journal-title":"J. Biol. Chem."},{"key":"23_CR139","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.bcp.2010.07.045","volume":"80","author":"AW Chua","year":"2010","unstructured":"Chua, A. W. et al. Butein downregulates chemokine receptor CXCR4 expression and function through suppression of NF-kappaB activation in breast and pancreatic tumor cells. Biochem. Pharmacol. \n                           80, 1553\u20131562 (2010).","journal-title":"Biochem. Pharmacol."},{"key":"23_CR140","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.canlet.2010.03.003","volume":"295","author":"HJ Maier","year":"2010","unstructured":"Maier, H. J. et al. NF-kappaB promotes epithelial-mesenchymal transition, migration and invasion of pancreatic carcinoma cells. Cancer Lett. \n                           295, 214\u2013228 (2010).","journal-title":"Cancer Lett."},{"key":"23_CR141","doi-asserted-by":"publisher","first-page":"5785","DOI":"10.1128\/MCB.19.8.5785","volume":"19","author":"DC Guttridge","year":"1999","unstructured":"Guttridge, D. C., Albanese, C., Reuther, J. Y., Pestell, R. G. & Baldwin, A. S. Jr. NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol. Cell Biol. \n                           19, 5785\u20135799 (1999).","journal-title":"Mol. Cell Biol."},{"key":"23_CR142","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1128\/MCB.19.4.2690","volume":"19","author":"M Hinz","year":"1999","unstructured":"Hinz, M. et al. NF-kappaB function in growth control: regulation of cyclin D1 expression and G0\/G1-to-S-phase transition. Mol. Cell Biol. \n                           19, 2690\u20132698 (1999).","journal-title":"Mol. Cell Biol."},{"key":"23_CR143","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/S0092-8674(01)00599-2","volume":"107","author":"Y Cao","year":"2001","unstructured":"Cao, Y. et al. IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. Cell \n                           107, 763\u2013775 (2001).","journal-title":"Cell"},{"key":"23_CR144","doi-asserted-by":"publisher","first-page":"10969","DOI":"10.18632\/oncotarget.2624","volume":"5","author":"L Prabhu","year":"2014","unstructured":"Prabhu, L., Mundade, R., Korc, M., Loehrer, P. J. & Lu, T. Critical role of NF-kappaB in pancreatic cancer. Oncotarget \n                           5, 10969\u201310975 (2014).","journal-title":"Oncotarget"},{"key":"23_CR145","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nature04870","volume":"441","author":"M Karin","year":"2006","unstructured":"Karin, M. Nuclear factor-kappaB in cancer development and progression. Nature \n                           441, 431\u2013436 (2006).","journal-title":"Nature"},{"key":"23_CR146","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/nrc780","volume":"2","author":"M Karin","year":"2002","unstructured":"Karin, M., Cao, Y., Greten, F. R. & Li, Z. W. NF-kappaB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer \n                           2, 301\u2013310 (2002).","journal-title":"Nat. Rev. Cancer"},{"key":"23_CR147","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1172\/JCI11914","volume":"107","author":"Y Yamamoto","year":"2001","unstructured":"Yamamoto, Y. & Gaynor, R. B. Therapeutic potential of inhibition of the NF-\u03baB pathway in the treatment of inflammation and cancer. J. Clin. Invest. \n                           107, 135\u2013142 (2001).","journal-title":"J. Clin. Invest."},{"key":"23_CR148","doi-asserted-by":"publisher","first-page":"6887","DOI":"10.1038\/sj.onc.1209982","volume":"25","author":"TD Gilmore","year":"2006","unstructured":"Gilmore, T. D. & Herscovitch, M. Inhibitors of NF-[kappa]B signaling: 785 and counting. Oncogene \n                           25, 6887\u20136899 (2006).","journal-title":"Oncogene"},{"key":"23_CR149","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.bbagrm.2010.05.004","volume":"1799","author":"SC Gupta","year":"2010","unstructured":"Gupta, S. C., Sundaram, C., Reuter, S. & Aggarwal, B. B. Inhibiting NF-\u03baB activation by small molecules as a therapeutic strategy. Biochim. Biophys. Acta \n                           1799, 775\u2013787 (2010).","journal-title":"Biochim. Biophys. Acta"},{"key":"23_CR150","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1093\/neuonc\/nov265","volume":"18","author":"KE Cahill","year":"2016","unstructured":"Cahill, K. E., Morshed, R. A. & Yamini, B. Nuclear factor-kappaB in glioblastoma: insights into regulators and targeted therapy. Neuro Oncol. \n                           18, 329\u2013339 (2016).","journal-title":"Neuro Oncol."},{"key":"23_CR151","doi-asserted-by":"crossref","unstructured":"Vogl, D. T. et al. Ricolinostat, the first selective histone deacetylase 6 inhibitor, in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma. Clin. Cancer Res. (2017).","DOI":"10.1158\/1078-0432.CCR-16-2526"},{"key":"23_CR152","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/nrc2681","volume":"10","author":"P Lopez-Bergami","year":"2010","unstructured":"Lopez-Bergami, P., Lau, E. & Ronai, Z. Emerging roles of ATF2 and the dynamic AP1 network in cancer. Nat. Rev. Cancer \n                           10, 65\u201376 (2010).","journal-title":"Nat. Rev. Cancer"},{"key":"23_CR153","doi-asserted-by":"publisher","first-page":"6930","DOI":"10.1021\/jm5004733","volume":"57","author":"N Ye","year":"2014","unstructured":"Ye, N. Small molecule inhibitors targeting activator protein 1 (AP-1) miniperspective. J. Med. Chem. \n                           57, 6930\u20136948 (2014).","journal-title":"J. Med. Chem."},{"key":"23_CR154","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1186\/1471-2407-13-441","volume":"13","author":"A Kharman-Biz","year":"2013","unstructured":"Kharman-Biz, A. et al. Expression of activator protein-1 (AP-1) family members in breast cancer. BMC Cancer \n                           13, 441 (2013).","journal-title":"BMC Cancer"},{"key":"23_CR155","doi-asserted-by":"publisher","first-page":"5370","DOI":"10.1128\/MCB.13.9.5370","volume":"13","author":"LJ Walker","year":"1993","unstructured":"Walker, L. J., Robson, C. N., Black, E., Gillespie, D. & Hickson, I. D. Identification of residues in the human DNA repair enzyme HAP1 (Ref-1) that are essential for redox regulation of Jun DNA binding. Mol. Cell Biol. \n                           13, 5370\u20135376 (1993).","journal-title":"Mol. Cell Biol."},{"key":"23_CR156","doi-asserted-by":"publisher","first-page":"5609","DOI":"10.1093\/emboj\/18.20.5609","volume":"18","author":"C Gaiddon","year":"1999","unstructured":"Gaiddon, C., Moorthy, N. C. & Prives, C. Ref-1 regulates the transactivation and pro-apoptotic functions of p53 in vivo. EMBO J. \n                           18, 5609\u20135621 (1999).","journal-title":"EMBO J."},{"key":"23_CR157","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1101\/gad.11.5.558","volume":"11","author":"L Jayaraman","year":"1997","unstructured":"Jayaraman, L. et al. Identification of redox\/repair protein Ref-1 as a potent activator of p53. Genes Dev. \n                           11, 558\u2013570 (1997).","journal-title":"Genes Dev."},{"key":"23_CR158","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.molmed.2016.05.002","volume":"22","author":"S Menegon","year":"2016","unstructured":"Menegon, S., Columbano, A. & Giordano, S. The dual roles of NRF2 in cancer. Trends Mol. Med. \n                           22, 578\u2013593 (2016).","journal-title":"Trends Mol. Med."},{"key":"23_CR159","doi-asserted-by":"publisher","first-page":"901","DOI":"10.2147\/DDDT.S75152","volume":"9","author":"Y Qing","year":"2015","unstructured":"Qing, Y. et al. Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer. Drug Des Devel. Ther. \n                           9, 901\u2013909 (2015).","journal-title":"Drug Des Devel. Ther."},{"key":"23_CR160","doi-asserted-by":"publisher","first-page":"e0143289","DOI":"10.1371\/journal.pone.0143289","volume":"10","author":"V Di Maso","year":"2015","unstructured":"Di Maso, V. et al. Transcriptional up-regulation of APE1\/Ref-1 in hepatic tumor: role in hepatocytes resistance to oxidative stress and apoptosis. PLoS One \n                           10, e0143289 (2015).","journal-title":"PLoS One"},{"key":"23_CR161","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1038\/bjc.1998.194","volume":"77","author":"S Kakolyris","year":"1998","unstructured":"Kakolyris, S. et al. Human AP endonuclease 1 (HAP1) protein expression in breast cancer correlates with lymph node status and angiogenesis. Br. J. Cancer \n                           77, 1169\u20131173 (1998).","journal-title":"Br. J. Cancer"},{"key":"23_CR162","doi-asserted-by":"publisher","first-page":"7405","DOI":"10.1158\/1078-0432.CCR-05-1068","volume":"11","author":"MS Bobola","year":"2005","unstructured":"Bobola, M. S. et al. Apurinic\/apyrimidinic endonuclease activity is associated with response to radiation and chemotherapy in medulloblastoma and primitive neuroectodermal tumors. Clin. Cancer Res. \n                           11, 7405\u20137414 (2005).","journal-title":"Clin. Cancer Res."},{"key":"23_CR163","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0360-3016(00)01561-3","volume":"50","author":"MI Koukourakis","year":"2001","unstructured":"Koukourakis, M. I. et al. Nuclear expression of human apurinic\/apyrimidinic endonuclease (HAP1\/Ref-1) in head-and-neck cancer is associated with resistance to chemoradiotherapy and poor outcome. Int. J. Radiat. Oncol. Biol. Phys. \n                           50, 27\u201336 (2001).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"23_CR164","first-page":"824","volume":"7","author":"MR Kelley","year":"2001","unstructured":"Kelley, M. R. et al. Elevated and altered expression of the multifunctional DNA base excision repair and redox enzyme Ape1\/ref-1 in prostate cancer. Clin. Cancer Res. \n                           7, 824\u2013830 (2001).","journal-title":"Clin. Cancer Res."},{"key":"23_CR165","first-page":"1225","volume":"60","author":"Z Ni","year":"2000","unstructured":"Ni, Z., Lou, W., Leman, E. S. & Gao, A. C. Inhibition of constitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells. Cancer Res. \n                           60, 1225\u20131228 (2000).","journal-title":"Cancer Res."},{"key":"23_CR166","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/pros.10079","volume":"51","author":"R Dhir","year":"2002","unstructured":"Dhir, R. et al. Stat3 activation in prostatic carcinomas. Prostate \n                           51, 241\u2013246 (2002).","journal-title":"Prostate"},{"key":"23_CR167","first-page":"6659","volume":"62","author":"LB Mora","year":"2002","unstructured":"Mora, L. B. et al. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res. \n                           62, 6659\u20136666 (2002).","journal-title":"Cancer Res."},{"key":"23_CR168","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/sj.bjc.6603871","volume":"97","author":"L Tam","year":"2007","unstructured":"Tam, L. et al. Expression levels of the JAK\/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer. Br. J. Cancer \n                           97, 378\u2013383 (2007).","journal-title":"Br. J. Cancer"},{"key":"23_CR169","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s12253-011-9410-y","volume":"18","author":"X Liu","year":"2012","unstructured":"Liu, X. et al. Correlation analysis of JAK-STAT pathway components on prognosis of patients with prostate cancer. Pathol. Oncol. Res. \n                           18, 17\u201323 (2012).","journal-title":"Pathol. Oncol. Res."},{"key":"23_CR170","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.eururo.2016.06.018","volume":"71","author":"N Don-Doncow","year":"2017","unstructured":"Don-Doncow, N. et al. Expression of STAT3 in Prostate Cancer Metastases. Eur. Urol. \n                           71, 313\u2013316 (2017).","journal-title":"Eur. Urol."},{"key":"23_CR171","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/cncr.20039","volume":"100","author":"SF Shariat","year":"2004","unstructured":"Shariat, S. F. et al. Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer \n                           100, 751\u2013757 (2004).","journal-title":"Cancer"},{"key":"23_CR172","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.urology.2007.12.064","volume":"72","author":"H Koike","year":"2008","unstructured":"Koike, H., Sekine, Y., Kamiya, M., Nakazato, H. & Suzuki, K. Gene expression of survivin and its spliced isoforms associated with proliferation and aggressive phenotypes of prostate cancer. Urology \n                           72, 1229\u20131233 (2008).","journal-title":"Urology"},{"key":"23_CR173","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1093\/abbs\/gmp005","volume":"41","author":"J Shen","year":"2009","unstructured":"Shen, J. et al. Knockdown of survivin expression by siRNAs enhances chemosensitivity of prostate cancer cells and attenuates its tumorigenicity. Acta Biochim. Biophys. Sin. (Shanghai) \n                           41, 223\u2013230 (2009).","journal-title":"Acta Biochim. Biophys. Sin. (Shanghai)"},{"key":"23_CR174","doi-asserted-by":"crossref","unstructured":"McIlwain, D. W., Fishel, M. L., Kelley, M. R. & Jerde, T. J. APE1\/Ref-1 redox-specific inhibition decreases survivin protein levels and induces cell arrest in prostate cancer cells. Oncotarget. Accepted with Minor Revisions. (2017).","DOI":"10.18632\/oncotarget.23493"},{"key":"23_CR175","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2016. CA Cancer J. Clin. \n                           66, 7\u201330 (2016).","journal-title":"CA Cancer J. Clin."},{"key":"23_CR176","first-page":"1794","volume":"57","author":"S Kakolyris","year":"1997","unstructured":"Kakolyris, S. et al. Human apurinic endonuclease 1 expression in a colorectal adenoma-carcinoma sequence. Cancer Res. \n                           57, 1794\u20131797 (1997).","journal-title":"Cancer Res."},{"key":"23_CR177","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.humpath.2007.04.024","volume":"39","author":"T Noike","year":"2008","unstructured":"Noike, T., Miwa, S., Soeda, J., Kobayashi, A. & Miyagawa, S. Increased expression of thioredoxin-1, vascular endothelial growth factor, and redox factor-1 is associated with poor prognosis in patients with liver metastasis from colorectal cancer. Hum. Pathol. \n                           39, 201\u2013208 (2008).","journal-title":"Hum. Pathol."},{"key":"23_CR178","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/cgt.2008.30","volume":"15","author":"DB Xiang","year":"2008","unstructured":"Xiang, D. B. et al. Chimeric adenoviral vector Ad5\/F35-mediated APE1 siRNA enhances sensitivity of human colorectal cancer cells to radiotherapy in vitro and in vivo. Cancer Gene Ther \n                           15, 625\u2013635 (2008).","journal-title":"Cancer Gene Ther"},{"key":"23_CR179","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.3892\/ol.2014.1864","volume":"7","author":"D Lou","year":"2014","unstructured":"Lou, D., Zhu, L., Ding, H., Dai, H. Y. & Zou, G. M. Aberrant expression of redox protein Ape1 in colon cancer stem cells. Oncol. Lett. \n                           7, 1078\u20131082 (2014).","journal-title":"Oncol. Lett."},{"key":"23_CR180","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1126\/science.1164368","volume":"321","author":"S Jones","year":"2008","unstructured":"Jones, S. et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science \n                           321, 1801\u20131806 (2008).","journal-title":"Science"},{"key":"23_CR181","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nature11547","volume":"491","author":"AV Biankin","year":"2012","unstructured":"Biankin, A. V. et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature \n                           491, 399\u2013405 (2012).","journal-title":"Nature"},{"key":"23_CR182","unstructured":"Rucki, A. A. et al. Heterogeneous stromal signaling within the tumor microenvironment controls the metastasis of pancreatic cancer. Cancer Res. (2016)."},{"key":"23_CR183","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1158\/0008-5472.CAN-10-4049","volume":"71","author":"Q Chang","year":"2011","unstructured":"Chang, Q., Jurisica, I., Do, T. & Hedley, D. W. Hypoxia predicts aggressive growth and spontaneous metastasis formation from orthotopically grown primary xenografts of human pancreatic cancer. Cancer. Res. \n                           71, 3110\u20133120 (2011).","journal-title":"Cancer. Res."},{"key":"23_CR184","first-page":"379","volume":"31","author":"A Jedinak","year":"2011","unstructured":"Jedinak, A., Dudhgaonkar, S., Kelley, M. R. & Sliva, D. Apurinic\/Apyrimidinic endonuclease 1 regulates inflammatory response in macrophages. Anticancer Res. \n                           31, 379\u2013385 (2011).","journal-title":"Anticancer Res."},{"key":"23_CR185","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/jcp.21666","volume":"219","author":"GM Zou","year":"2009","unstructured":"Zou, G. M. et al. The Ape-1\/Ref-1 redox antagonist E3330 inhibits the growth of tumor endothelium and endothelial progenitor cells: therapeutic implications in tumor angiogenesis. J. Cell. Physiol. \n                           219, 209\u2013218 (2009).","journal-title":"J. Cell. Physiol."},{"key":"23_CR186","first-page":"602","volume":"6","author":"DH Moore","year":"2000","unstructured":"Moore, D. H., Michael, H., Tritt, R., Parsons, S. H. & Kelley, M. R. Alterations in the expression of the DNA repair\/redox enzyme APE\/ref-1 in epithelial ovarian cancers. Clin. Cancer Res. \n                           6, 602\u2013609 (2000).","journal-title":"Clin. Cancer Res."},{"key":"23_CR187","doi-asserted-by":"crossref","unstructured":"Kong, Q., Wang, W., Luo, L. & Sun, X. Silencing of apurinic\/apyrimidinic endonuclease 1 inhibits the growth and migration in ovarian cancer cell via activator-protein-1 signaling. Gynecol. Obstet. Invest. (2016).","DOI":"10.1159\/000447261"},{"key":"23_CR188","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s12032-011-9931-y","volume":"29","author":"Q Sheng","year":"2012","unstructured":"Sheng, Q. et al. Prognostic significance of APE1 cytoplasmic localization in human epithelial ovarian cancer. Med. Oncol. \n                           29, 1265\u20131271 (2012).","journal-title":"Med. Oncol."},{"key":"23_CR189","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.3892\/ijo_00000369","volume":"35","author":"Y Zhang","year":"2009","unstructured":"Zhang, Y. Alterations in the expression of the apurinic\/apyrimidinic endonuclease-1\/redox factor-1 (APE1\/Ref-1) in human ovarian cancer and indentification of the therapeutic potential of APE1\/Ref-1 inhibitor. Int. J. Oncol. \n                           35, 1069\u20131079 (2009).","journal-title":"Int. J. Oncol."},{"key":"23_CR190","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.ygyno.2003.10.037","volume":"92","author":"B Tanner","year":"2004","unstructured":"Tanner, B. et al. Nuclear expression of apurinic\/apyrimidinic endonuclease increases with progression of ovarian carcinomas. Gynecol. Oncol. \n                           92, 568\u2013577 (2004).","journal-title":"Gynecol. Oncol."},{"key":"23_CR191","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/sj.bjc.6605541","volume":"102","author":"A Al-Attar","year":"2010","unstructured":"Al-Attar, A. et al. Human apurinic\/apyrimidinic endonuclease (APE1) is a prognostic factor in ovarian, gastro-oesophageal and pancreatico-biliary cancers. Br. J. Cancer \n                           102, 704\u2013709 (2010).","journal-title":"Br. J. Cancer"},{"key":"23_CR192","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3233\/CBM-160643","volume":"17","author":"X Wen","year":"2016","unstructured":"Wen, X. et al. APE1 overexpression promotes the progression of ovarian cancer and serves as a potential therapeutic target. Cancer Biomark. \n                           17, 313\u2013322 (2016).","journal-title":"Cancer Biomark."},{"key":"23_CR193","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.lungcan.2007.10.015","volume":"60","author":"DG Yoo","year":"2008","unstructured":"Yoo, D. G. et al. Alteration of APE1\/ref-1 expression in non-small cell lung cancer: The implications of impaired extracellular superoxide dismutase and catalase antioxidant systems. Lung. Cancer \n                           60, 227\u201384 (2008).","journal-title":"Lung. Cancer"},{"key":"23_CR194","doi-asserted-by":"publisher","first-page":"870","DOI":"10.7150\/ijms.5727","volume":"10","author":"X Gu","year":"2013","unstructured":"Gu, X. et al. Human apurinic\/apyrimidinic endonuclease siRNA inhibits the angiogenesis induced by X-Ray irradiation in lung cancer cells. Int. J. Med. Sci. \n                           10, 870\u2013882 (2013).","journal-title":"Int. J. Med. Sci."},{"key":"23_CR195","doi-asserted-by":"crossref","first-page":"28523","DOI":"10.18632\/oncotarget.8660","volume":"7","author":"X Wei","year":"2016","unstructured":"Wei, X. et al. Prediction of survival prognosis of non-small cell lung cancer by APE1 through regulation of epithelial-mesenchymal transition. Oncotarget \n                           7, 28523\u201328539 (2016).","journal-title":"Oncotarget"},{"key":"23_CR196","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1002\/(SICI)1096-9896(199911)189:3<351::AID-PATH435>3.0.CO;2-1","volume":"189","author":"S Kakolyris","year":"1999","unstructured":"Kakolyris, S. et al. Nuclear localization of human AP endonuclease 1 (HAP1\/Ref-1) associates with prognosis in early operable non-small cell lung cancer (NSCLC). J. Pathol. \n                           189, 351\u2013357 (1999).","journal-title":"J. Pathol."},{"key":"23_CR197","first-page":"4041","volume":"21","author":"F Puglisi","year":"2001","unstructured":"Puglisi, F. et al. Prognostic significance of Ape1\/ref-1 subcellular localization in non- small cell lung carcinomas. Anticancer Res. \n                           21, 4041\u20134049 (2001).","journal-title":"Anticancer Res."},{"key":"23_CR198","doi-asserted-by":"crossref","unstructured":"Wu, H. H. et al. Cytoplasmic ape1 expression elevated by p53 aberration may predict survival and relapse in resected non-small cell lung cancer. Ann. Surg. Oncol. (2012).","DOI":"10.1245\/s10434-012-2431-2"},{"key":"23_CR199","doi-asserted-by":"publisher","first-page":"4330","DOI":"10.1038\/onc.2010.178","volume":"29","author":"HH Wu","year":"2010","unstructured":"Wu, H. H. et al. Subcellular localization of apurinic endonuclease 1 promotes lung tumor aggressiveness via NF-kappaB activation. Oncogene \n                           29, 4330\u201340 (2010).","journal-title":"Oncogene"},{"key":"23_CR200","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1177\/0218492311432800","volume":"20","author":"MW Kang","year":"2012","unstructured":"Kang, M. W. et al. Upregulation of APE\/ref-1 in recurrence stage I, non small cell lung cancer. Asian Cardiovasc. Thorac. Ann. \n                           20, 36\u201341 (2012).","journal-title":"Asian Cardiovasc. Thorac. Ann."},{"key":"23_CR201","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1002\/cam4.675","volume":"5","author":"Y Zhang","year":"2016","unstructured":"Zhang, Y. et al. Suppression of prostate cancer progression by cancer cell stemness inhibitor napabucasin. Cancer Med. \n                           5, 1251\u20131258 (2016).","journal-title":"Cancer Med."},{"key":"23_CR202","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.lungcan.2009.02.019","volume":"66","author":"D Wang","year":"2009","unstructured":"Wang, D. et al. APE1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cells. Lung Cancer \n                           66, 298\u2013304 (2009).","journal-title":"Lung Cancer"},{"key":"23_CR203","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s00280-014-2562-1","volume":"74","author":"Z Li","year":"2014","unstructured":"Li, Z. et al. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy. Cancer Chemother. Pharmacol. \n                           74, 777\u2013786 (2014).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"23_CR204","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/j.1349-7006.2009.01366.x","volume":"101","author":"ZZ Yang","year":"2010","unstructured":"Yang, Z. Z. et al. Knock down of the dual functional protein apurinic \/apyrimidinic endonuclease 1 enhances the killing effect of hematoporphrphyrin derivative-mediated photodynamic therapy on non-small cell lung cancer cells in vitro and in a xenograft model. Cancer. Sci \n                           101, 180\u2013187 (2010).","journal-title":"Cancer. Sci"},{"key":"23_CR205","doi-asserted-by":"crossref","unstructured":"Wang, Z. et al. Reduced apurinic\/apyrimidinic endonuclease activity enhances the antitumor activity of oxymatrine in lung cancer cells. Int. J. Oncol. (2016).","DOI":"10.3892\/ijo.2016.3734"},{"key":"23_CR206","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1634\/theoncologist.2013-0328","volume":"19","author":"M Farid","year":"2014","unstructured":"Farid, M. et al. Malignant peripheral nerve sheath tumors. Oncologist \n                           19, 193\u2013201 (2014).","journal-title":"Oncologist"},{"key":"23_CR207","doi-asserted-by":"crossref","unstructured":"Panse, G. et al. The role of phosphorylated signal transducer and activator of transcription 3 (pSTAT3) in peripheral nerve sheath tumors. Histopathology (2016).","DOI":"10.1111\/his.13154"},{"key":"23_CR208","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/onc.2012.579","volume":"33","author":"J Wu","year":"2014","unstructured":"Wu, J. et al. EGFR-STAT3 signaling promotes formation of malignant peripheral nerve sheath tumors. Oncogene \n                           33, 173\u2013180 (2014).","journal-title":"Oncogene"},{"key":"23_CR209","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/path.1998","volume":"209","author":"CT Storlazzi","year":"2006","unstructured":"Storlazzi, C. T. et al. Identification of a novel amplicon at distal 17q containing the BIRC5\/SURVIVIN gene in malignant peripheral nerve sheath tumours. J. Pathol. \n                           209, 492\u2013500 (2006).","journal-title":"J. Pathol."},{"key":"23_CR210","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1158\/1078-0432.CCR-11-2592","volume":"18","author":"MP Ghadimi","year":"2012","unstructured":"Ghadimi, M. P. et al. Survivin is a viable target for the treatment of malignant peripheral nerve sheath tumors. Clin. Cancer Res. \n                           18, 2545\u20132557 (2012).","journal-title":"Clin. Cancer Res."},{"key":"23_CR211","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1182\/blood-2008-04-150250","volume":"113","author":"MA Sanz","year":"2009","unstructured":"Sanz, M. A. et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood \n                           113, 1875\u20131891 (2009).","journal-title":"Blood"},{"key":"23_CR212","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1182\/blood-2008-07-168617","volume":"113","author":"P Montesinos","year":"2009","unstructured":"Montesinos, P. et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood \n                           113, 775\u2013783 (2009).","journal-title":"Blood"},{"key":"23_CR213","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0037-1963(01)90002-2","volume":"38","author":"P Fenaux","year":"2001","unstructured":"Fenaux, P., Chomienne, C. & Degos, L. All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia. Semin. Hematol. \n                           38, 13\u201325 (2001).","journal-title":"Semin. Hematol."},{"key":"23_CR214","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1053\/beha.2000.0121","volume":"14","author":"P Fenaux","year":"2001","unstructured":"Fenaux, P., Chomienne, C. & Degos, L. Treatment of acute promyelocytic leukaemia. Best Pract. Res. Clin. Haematol. \n                           14, 153\u2013174 (2001).","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"23_CR215","doi-asserted-by":"publisher","first-page":"378","DOI":"10.3109\/02713683.2014.924148","volume":"40","author":"B Xu","year":"2015","unstructured":"Xu, B. et al. The changes of 8-OHdG, hOGG1, APE1 and Pol beta in lenses of patients with age-related cataract. Curr. Eye Res. \n                           40, 378\u2013385 (2015).","journal-title":"Curr. Eye Res."},{"key":"23_CR216","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/sj.cdd.4400639","volume":"7","author":"LB Chiarini","year":"2000","unstructured":"Chiarini, L. B., Freitas, F. G., Petrs-Silva, H. & Linden, R. Evidence that the bifunctional redox factor \/ AP endonuclease Ref-1 is an anti-apoptotic protein associated with differentiation in the developing retina. Cell Death Differ. \n                           7, 272\u2013281 (2000).","journal-title":"Cell Death Differ."},{"key":"23_CR217","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.visres.2010.10.008","volume":"51","author":"A Jiang","year":"2011","unstructured":"Jiang, A., Gao, H., Kelley, M. R. & Qiao, X. Inhibition of APE1\/Ref-1 redox activity with APX3330 blocks retinal angiogenesis in vitro and in vivo. Vis. Res. \n                           51, 93\u2013100 (2011).","journal-title":"Vis. Res."},{"key":"23_CR218","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.redox.2014.01.023","volume":"2","author":"Y Li","year":"2014","unstructured":"Li, Y. et al. Inhibition of APE1\/Ref-1 redox activity rescues human retinal pigment epithelial cells from oxidative stress and reduces choroidal neovascularization. Redox Biol. \n                           2, 485\u2013494 (2014).","journal-title":"Redox Biol."},{"key":"23_CR219","doi-asserted-by":"crossref","unstructured":"Li, Y. et al. Suppression of choroidal neovascularization through inhibition of APE1\/Ref-1 redox activity. Invest. Ophthalmol. Vis. Sci. (2014).","DOI":"10.1167\/iovs.14-14451"},{"key":"23_CR220","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/jcp.21566","volume":"218","author":"J Jiang","year":"2009","unstructured":"Jiang, J. et al. Inhibition of retinal neovascularization by gene transfer of small interfering RNA targeting HIF-1alpha and VEGF. J. Cell. Physiol. \n                           218, 66\u201374 (2009).","journal-title":"J. Cell. Physiol."},{"key":"23_CR221","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jcjo.2012.03.026","volume":"47","author":"S Sharma","year":"2012","unstructured":"Sharma, S., Johnson, D., Abouammoh, M., Hollands, S. & Brissette, A. Rate of serious adverse effects in a series of bevacizumab and ranibizumab injections. Can. J. Ophthalmol. \n                           47, 275\u2013279 (2012).","journal-title":"Can. J. Ophthalmol."},{"key":"23_CR222","doi-asserted-by":"crossref","unstructured":"Song, S. H. et al. Redox regulating protein APE1\/Ref-1 expression is increased in abdominal aortic coarctation-induced hypertension rats. J. Korean Soc. Hypertens, 18, 126\u2013135 (2012).","DOI":"10.5646\/jksh.2012.18.3.126"},{"key":"23_CR223","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1161\/01.RES.0000146947.84294.4c","volume":"95","author":"BH Jeon","year":"2004","unstructured":"Jeon, B. H. et al. Apurinic\/apyrimidinic endonuclease 1 regulates endothelial NO production and vascular tone. Circ. Res. \n                           95, 902\u2013910 (2004).","journal-title":"Circ. Res."},{"key":"23_CR224","doi-asserted-by":"publisher","first-page":"e1000327","DOI":"10.1371\/journal.ppat.1000327","volume":"5","author":"N Yan","year":"2009","unstructured":"Yan, N., Cherepanov, P., Daigle, J. E., Engelman, A. & Lieberman, J. The SET complex acts as a barrier to autointegration of HIV-1. PLoS Pathog. \n                           5, e1000327 (2009).","journal-title":"PLoS Pathog."},{"key":"23_CR225","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1053\/j.gastro.2004.06.017","volume":"127","author":"SZ Ding","year":"2004","unstructured":"Ding, S. Z. et al. Helicobacter pylori and H2O2 increase AP endonuclease-1\/redox factor-1 expression in human gastric epithelial cells. Gastroenterology \n                           127, 845\u2013858 (2004).","journal-title":"Gastroenterology"},{"key":"23_CR226","doi-asserted-by":"publisher","first-page":"e1005382","DOI":"10.1371\/journal.ppat.1005382","volume":"12","author":"G den Hartog","year":"2016","unstructured":"den Hartog, G. et al. Regulation of Rac1 and reactive oxygen species production in response to infection of gastrointestinal Epithelia. PLoS Pathog. \n                           12, e1005382 (2016).","journal-title":"PLoS Pathog."},{"key":"23_CR227","doi-asserted-by":"publisher","first-page":"7990","DOI":"10.4049\/jimmunol.177.11.7990","volume":"177","author":"AM O\u2019Hara","year":"2006","unstructured":"O\u2019Hara, A. M. et al. Interleukin-8 induction by Helicobacter pylori in gastric epithelial cells is dependent on apurinic\/apyrimidinic endonuclease-1\/redox factor-1. J. Immunol. (Baltimore, Md.: 1950) \n                           177, 7990\u20137999 (2006).","journal-title":"J. Immunol. (Baltimore, Md.: 1950)"},{"key":"23_CR228","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.cyto.2009.03.010","volume":"46","author":"AM O\u2019Hara","year":"2009","unstructured":"O\u2019Hara, A. M. et al. Tumor necrosis factor (TNF)-alpha-induced IL-8 expression in gastric epithelial cells: role of reactive oxygen species and AP endonuclease-1\/redox factor (Ref)-1. Cytokine \n                           46, 359\u2013369 (2009).","journal-title":"Cytokine"},{"key":"23_CR229","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/S0197-4580(02)00229-4","volume":"24","author":"V Davydov","year":"2003","unstructured":"Davydov, V., Hansen, L. A. & Shackelford, D. A. Is DNA repair compromised in Alzheimer\u2019s disease? Neurobiol. Aging \n                           24, 953\u2013968 (2003).","journal-title":"Neurobiol. Aging"},{"key":"23_CR230","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.neulet.2009.09.039","volume":"466","author":"G Marcon","year":"2009","unstructured":"Marcon, G. et al. APE1\/Ref-1 in Alzheimer\u2019s disease: an immunohistochemical study. Neurosci. Lett. \n                           466, 124\u2013127 (2009).","journal-title":"Neurosci. Lett."},{"key":"23_CR231","doi-asserted-by":"publisher","first-page":"793","DOI":"10.18632\/aging.100810","volume":"7","author":"S Maynard","year":"2015","unstructured":"Maynard, S. et al. Defective mitochondrial respiration, altered dNTP pools and reduced AP endonuclease 1 activity in peripheral blood mononuclear cells of Alzheimer\u2019s disease patients. Aging (Albany NY) \n                           7, 793\u2013815 (2015).","journal-title":"Aging (Albany NY)"},{"key":"23_CR232","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s12017-002-0038-7","volume":"2","author":"AY Shaikh","year":"2002","unstructured":"Shaikh, A. Y. & Martin, L. J. DNA base-excision repair enzyme apurinic\/apyrimidinic endonuclease\/redox factor-1 is increased and competent in the brain and spinal cord of individuals with amyotrophic lateral sclerosis. Neuromolecular Med. \n                           2, 47\u201360 (2002).","journal-title":"Neuromolecular Med."},{"key":"23_CR233","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1089\/gtmb.2011.0252","volume":"16","author":"M Gencer","year":"2012","unstructured":"Gencer, M. et al. DNA repair genes in Parkinson\u2019s disease. Gene Test Mol. Biomark. \n                           16, 504\u2013507 (2012).","journal-title":"Gene Test Mol. Biomark."},{"key":"23_CR234","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.freeradbiomed.2015.09.017","volume":"89","author":"N Xia","year":"2015","unstructured":"Xia, N. et al. Blockade of metabotropic glutamate receptor 5 protects against DNA damage in a rotenone-induced Parkinson\u2019s disease model. Free Radic. Biol. Med. \n                           89, 567\u2013580 (2015).","journal-title":"Free Radic. Biol. Med."},{"key":"23_CR235","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/WNR.0000000000000712","volume":"28","author":"B Kang","year":"2017","unstructured":"Kang, B. et al. Ape1 protects against MPP+-induced neurotoxicity through ERK1\/2 signaling in PC12 cells. Neuroreport \n                           28, 10\u201316 (2017).","journal-title":"Neuroreport"},{"key":"23_CR236","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1089\/ars.2013.5511","volume":"22","author":"RK Leak","year":"2015","unstructured":"Leak, R. K. et al. Apurinic\/apyrimidinic endonuclease 1 upregulation reduces oxidative DNA damage and protects hippocampal neurons from ischemic injury. Antioxid. Redox Signal. \n                           22, 135\u2013148 (2015).","journal-title":"Antioxid. Redox Signal."},{"key":"23_CR237","doi-asserted-by":"crossref","unstructured":"Stetler, R. A. et al. APE1\/Ref-1 facilitates recovery of gray and white matter and neurological function after mild stroke injury. Proc. Natl. Acad. Sci. (2016).","DOI":"10.1073\/pnas.1606226113"},{"key":"23_CR238","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3390\/cancers6010226","volume":"6","author":"MM Inda","year":"2014","unstructured":"Inda, M. M., Bonavia, R. & Seoane, J. Glioblastoma multiforme: a look inside its heterogeneous nature. Cancers \n                           6, 226\u2013239 (2014).","journal-title":"Cancers"},{"key":"23_CR239","unstructured":"Kelley, M. R. & Fishel, M. L. (eds). DNA Repair in Cancer Therapy: Molecular Targets and Clinical Applications. 2nd edn, (Academic, 2015)."},{"key":"23_CR240","doi-asserted-by":"crossref","unstructured":"Sultana, R. et al. Synthetic lethal targeting of DNA double-strand break repair deficient cells by human apurinic\/apyrimidinic endonuclease inhibitors. Int. J. Cancer \n                           131, 2433-2444 (2012).","DOI":"10.1002\/ijc.27512"},{"key":"23_CR241","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1002\/mc.22313","volume":"55","author":"M Poletto","year":"2016","unstructured":"Poletto, M. et al. Inhibitors of the apurinic\/apyrimidinic endonuclease 1 (APE1)\/nucleophosmin (NPM1) interaction that display anti-tumor properties. Mol. Carcinog. \n                           55, 688\u2013704 (2016).","journal-title":"Mol. Carcinog."},{"key":"23_CR242","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1111\/j.1349-7006.2007.00616.x","volume":"98","author":"D Wang","year":"2007","unstructured":"Wang, D., Zhong, Z. Y., Li, M. X., Xiang, D. B. & Li, Z. P. Vector-based Ape1 small interfering RNA enhances the sensitivity of human osteosarcoma cells to endostatin in vivo. Cancer Sci. \n                           98, 1993\u20132001 (2007).","journal-title":"Cancer Sci."},{"key":"23_CR243","doi-asserted-by":"crossref","unstructured":"Pinzon-Daza, M. L. et al. Oxidative stress promotes doxorubicin-induced Pgp and BCRP expression in colon cancer cells under hypoxic conditions. J. Cell. Biochem. (2017).","DOI":"10.1002\/jcb.25890"},{"key":"23_CR244","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.2147\/DDDT.S71432","volume":"8","author":"T Ren","year":"2014","unstructured":"Ren, T. et al. Sequential treatment with AT-101 enhances cisplatin chemosensitivity in human non-small cell lung cancer cells through inhibition of apurinic\/apyrimidinic endonuclease 1-activated IL-6\/STAT3 signaling pathway. Drug Des. Devel. Ther. \n                           8, 2517\u20132529 (2014).","journal-title":"Drug Des. Devel. Ther."},{"key":"23_CR245","doi-asserted-by":"crossref","unstructured":"Sawant, A. et al. Differential role of base excision repair proteins in mediating cisplatin cytotoxicity. DNA Repair (Amst) (2017).","DOI":"10.1016\/j.dnarep.2017.01.002"},{"key":"23_CR246","doi-asserted-by":"crossref","first-page":"610","DOI":"10.3892\/ijo.2015.3048","volume":"47","author":"S Jiang","year":"2015","unstructured":"Jiang, S. et al. Ape1 regulates WNT\/beta-catenin signaling through its redox functional domain in pancreatic cancer cells. Int. J. Oncol. \n                           47, 610\u2013620 (2015).","journal-title":"Int. J. Oncol."},{"key":"23_CR247","doi-asserted-by":"crossref","first-page":"55352","DOI":"10.18632\/oncotarget.10536","volume":"7","author":"H Ye","year":"2016","unstructured":"Ye, H., Zhang, X., Chen, Y., Liu, Q. & Wei, J. Ranking novel cancer driving synthetic lethal gene pairs using TCGA data. Oncotarget \n                           7, 55352\u201355367 (2016).","journal-title":"Oncotarget"},{"key":"23_CR248","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1056\/NEJMra1407390","volume":"371","author":"DP McLornan","year":"2014","unstructured":"McLornan, D. P., List, A. & Mufti, G. J. Applying synthetic lethality for the selective targeting of cancer. N. Engl. J. Med. \n                           371, 1725\u20131735 (2014).","journal-title":"N. Engl. J. Med."},{"key":"23_CR249","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.2147\/DDDT.S60328","volume":"9","author":"EG Chiorean","year":"2015","unstructured":"Chiorean, E. G. & Coveler, A. L. Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies. Drug Des. Devel. Ther. \n                           9, 3529\u20133545 (2015).","journal-title":"Drug Des. Devel. Ther."},{"key":"23_CR250","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1002\/pmic.200800638","volume":"9","author":"C Vascotto","year":"2009","unstructured":"Vascotto, C. et al. Genome-wide analysis and proteomic studies reveal APE1\/Ref-1 multifunctional role in mammalian cells. Proteomics \n                           9, 1058\u20131074 (2009).","journal-title":"Proteomics"},{"key":"23_CR251","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","volume":"155","author":"M Seretny","year":"2014","unstructured":"Seretny, M. et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain \n                           155, 2461\u20132470 (2014).","journal-title":"Pain"},{"key":"23_CR252","doi-asserted-by":"crossref","unstructured":"Vasko, M. R., Shariati, B. & Zanville, N. in DNA Repair in Cancer Therapy 2nd edn (eds Mark, R., Fishel, K. & Melissa, L.) Ch. 13, 383\u2013428 (Academic, 2016).","DOI":"10.1016\/B978-0-12-803582-5.00013-9"},{"key":"23_CR253","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1124\/jpet.116.235283","volume":"359","author":"MR Kelley","year":"2016","unstructured":"Kelley, M. R. et al. Identification and characterization of new chemical entities targeting apurinic\/apyrimidinic endonuclease 1 for the prevention of chemotherapy-induced peripheral neuropathy (CIPN). J. Pharmacol. Exp. Ther. \n                           359, 300\u2013309 (2016).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"23_CR254","doi-asserted-by":"publisher","first-page":"e106485","DOI":"10.1371\/journal.pone.0106485","volume":"9","author":"MR Kelley","year":"2014","unstructured":"Kelley, M. R. et al. Role of the DNA base excision repair protein, APE1 in cisplatin, oxaliplatin, or carboplatin induced sensory neuropathy. PLoS One \n                           9, e106485 (2014).","journal-title":"PLoS One"},{"key":"23_CR255","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.dnarep.2009.08.003","volume":"8","author":"Y Jiang","year":"2009","unstructured":"Jiang, Y. et al. Role of APE1 in differentiated neuroblastoma SH-SY5Y cells in response to oxidative stress: use of APE1 small molecule inhibitors to delineate APE1 functions. DNA Repair (Amst). \n                           8, 1273\u20131282 (2009).","journal-title":"DNA Repair (Amst)."},{"key":"23_CR256","doi-asserted-by":"publisher","first-page":"6425","DOI":"10.1158\/0008-5472.CAN-08-1173","volume":"68","author":"Y Jiang","year":"2008","unstructured":"Jiang, Y., Guo, C., Vasko, M. R. & Kelley, M. R. Implications of apurinic\/apyrimidinic endonuclease in reactive oxygen signaling response after cisplatin treatment of dorsal root ganglion neurons. Cancer Res. \n                           68, 6425\u20136434 (2008).","journal-title":"Cancer Res."},{"key":"23_CR257","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.dnarep.2004.11.006","volume":"4","author":"MR Vasko","year":"2005","unstructured":"Vasko, M. R., Guo, C. & Kelley, M. R. The multifunctional DNA repair\/redox enzyme Ape1\/Ref-1 promotes survival of neurons after oxidative stress. DNA Repair (Amst). \n                           4, 367\u2013379 (2005).","journal-title":"DNA Repair (Amst)."},{"key":"23_CR258","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1089\/ars.2010.3410","volume":"14","author":"MR Kelley","year":"2011","unstructured":"Kelley, M. R. et al. Functional analysis of new and novel analogs of E3330 that block the redox signaling activity of the multifunctional AP endonuclease\/redox signaling enzyme APE1\/Ref-1. Antioxid. Redox. Signal. \n                           14, 1387\u20131401 (2011).","journal-title":"Antioxid. Redox. Signal."},{"key":"23_CR259","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1021\/jm9014857","volume":"53","author":"RL Nyland","year":"2010","unstructured":"Nyland, R. L., Luo, M., Kelley, M. R. & Borch, R. F. Design and synthesis of novel quinone inhibitors targeted to the redox function of apurinic\/apyrimidinic endonuclease 1\/redox enhancing factor-1 (Ape1\/ref-1). J. Med. Chem. \n                           53, 1200\u20131210 (2010).","journal-title":"J. Med. Chem."},{"key":"23_CR260","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1182\/blood-2006-08-044172","volume":"109","author":"GM Zou","year":"2007","unstructured":"Zou, G. M., Luo, M. H., Reed, A., Kelley, M. R. & Yoder, M. C. Ape1 regulates hematopoietic differentiation of embryonic stem cells through its redox functional domain. Blood \n                           109, 1917\u20131922 (2007).","journal-title":"Blood"},{"key":"23_CR261","doi-asserted-by":"crossref","unstructured":"Kelley, M. R. & Fishel, M.L. in DNA Repair in Cancer Therapy 2nd edn (eds Kelley, M. R. & Fishel, M.L.) Ch. 1, 1\u201347 (Academic, 2016).","DOI":"10.1016\/B978-0-12-803582-5.00001-2"},{"key":"23_CR262","doi-asserted-by":"crossref","unstructured":"Lirussi, L., Antoniali, G., D\u2019Ambrosio, C., Scaloni, A., Nilsen, H. & Tell, G. APE1 polymorphic variants cause persistent genomic stress and affect cancer cell proliferation. Oncotarget. 7, 26293\u201326306 (2016).","DOI":"10.18632\/oncotarget.8477"},{"key":"23_CR263","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-014-1829-9","author":"F Jin","year":"2014","unstructured":"Jin, F. et al. Genetic polymorphism of APE1 rs1130409 can contribute to the risk of lung cancer. Tumour Biol.. doi:10.1007\/s13277-014-1829-9 (2014).","journal-title":"Tumour Biol."},{"key":"23_CR264","doi-asserted-by":"publisher","first-page":"e31677","DOI":"10.1371\/journal.pone.0031677","volume":"7","author":"CGP Doss","year":"2012","unstructured":"Doss, C. G. P. & NagaSundaram, N. Investigating the structural impacts of I64T and P311S mutations in APE1-DNA complex: a molecular dynamics approach. PLoS One \n                           7, e31677 (2012).","journal-title":"PLoS One"},{"key":"23_CR265","unstructured":"Kelley, M. & Fishel, M. in Principles of Molecular Diagnostics and Personalized Cancer Therapy Ch. 43, 566\u2013579 (Lippincott Williams & Wilkins, 2013)."},{"key":"23_CR266","unstructured":"Fishel, M., Vascotto, C. & Kelley, M. in DNA Repair and Cancer: Bench to Clinic (eds Madhusudan, S & Wilson III, DM) 233\u2013287 (Science Publishers, 2013)."},{"key":"23_CR267","unstructured":"Kelley, M., Georgiadis, M. & Fishel, M. in The Tumor Microenvironment Cancer Drug Discovery and Development (ed R. G. Bagley) (Springer, 2010)."},{"key":"23_CR268","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.3892\/ijo_00000369","volume":"35","author":"Y Zhang","year":"2009","unstructured":"Zhang, Y., Wang, J., Xiang, D., Wang, D. & Xin, X. Alterations in the expression of the apurinic\/apyrimidinic endonuclease-1\/redox factor-1 (APE1\/Ref-1) in human ovarian cancer and indentification of the therapeutic potential of APE1\/Ref-1 inhibitor. Int. J. Oncol. \n                           35, 1069\u20131079 (2009).","journal-title":"Int. J. Oncol."},{"key":"23_CR269","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1089\/cbr.2012.1266","volume":"28","author":"S Chen","year":"2013","unstructured":"Chen, S., Xiong, G., Wu, S. & Mo, J. Downregulation of apurinic\/apyrimidinic endonuclease 1\/redox factor-1 enhances the sensitivity of human pancreatic cancer cells to radiotherapy in vitro. Cancer Biother. Radiopharm. \n                           28, 169\u2013176 (2013).","journal-title":"Cancer Biother. Radiopharm."},{"key":"23_CR270","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/bjc.1998.641","volume":"78","author":"CJ Herring","year":"1998","unstructured":"Herring, C. J. et al. Levels of the DNA repair enzyme human apurinic\/apyrimidinic endonuclease (APE1, APEX, Ref-1) are associated with the intrinsic radiosensitivity of cervical cancers. Br. J. Cancer \n                           78, 1128\u20131133 (1998).","journal-title":"Br. J. Cancer"},{"key":"23_CR271","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2119\/2006-00084.DiMaso","volume":"13","author":"V Di Maso","year":"2007","unstructured":"Di Maso, V. et al. Subcellular localization of APE1\/Ref-1 in human hepatocellular carcinoma: possible prognostic significance. Mol. Med. \n                           13, 89\u201396 (2007).","journal-title":"Mol. Med."},{"key":"23_CR272","first-page":"11","volume":"9","author":"F Puglisi","year":"2002","unstructured":"Puglisi, F. et al. Prognostic role of Ape\/Ref-1 subcellular expression in stage I-III breast carcinomas. Oncol. Rep. \n                           9, 11\u201317 (2002).","journal-title":"Oncol. Rep."},{"key":"23_CR273","doi-asserted-by":"publisher","first-page":"7276502","DOI":"10.1155\/2016\/7276502","volume":"2016","author":"S Choi","year":"2016","unstructured":"Choi, S. et al. Urinary APE1\/Ref-1: a potential bladder cancer biomarker. Dis. Markers \n                           2016, 7276502, doi:10.1155\/2016\/7276502 (2016).","journal-title":"Dis. Markers"},{"key":"23_CR274","doi-asserted-by":"publisher","first-page":"823","DOI":"10.4143\/crt.2014.074","volume":"47","author":"JH Shin","year":"2015","unstructured":"Shin, J. H. et al. APE1\/Ref-1 as a serological biomarker for the detection of bladder cancer. . Cancer Res. Treat. \n                           47, 823\u201333 (2015).","journal-title":". Cancer Res. Treat."},{"key":"23_CR275","doi-asserted-by":"publisher","first-page":"198","DOI":"10.4161\/cbt.12.3.15979","volume":"12","author":"LF Sempere","year":"2011","unstructured":"Sempere, L. F., Gunn, J. R. & Korc, M. A novel 3-dimensional culture system uncovers growth stimulatory actions by TGFbeta in pancreatic cancer cells. Cancer Biol. Ther. \n                           12, 198\u2013207 (2011).","journal-title":"Cancer Biol. Ther."},{"key":"23_CR276","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1177\/0192623311429972","volume":"40","author":"P Lindblom","year":"2012","unstructured":"Lindblom, P. et al. Tesaglitazar, a dual PPAR-alpha\/gamma agonist, hamster carcinogenicity, investigative animal and clinical studies. Toxicol. Pathol. \n                           40, 18\u201332 (2012).","journal-title":"Toxicol. Pathol."},{"key":"23_CR277","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/35000249","volume":"403","author":"CD Mol","year":"2000","unstructured":"Mol, C. D., Izumi, T., Mitra, S. & Tainer, J. A. DNA-bound structures and mutants reveal abasic DNA binding by APE1 and DNA repair coordination [corrected]. Nature \n                           403, 451\u2013456 (2000).","journal-title":"Nature"},{"key":"23_CR278","doi-asserted-by":"publisher","first-page":"72","DOI":"10.4103\/1673-5374.198986","volume":"12","author":"MR Kelley","year":"2017","unstructured":"Kelley, M. R. & Fehrenbacher, J. C. Challenges and opportunities identifying therapeutic targets for chemotherapy-induced peripheral neuropathy resulting from oxidative DNA damage. Neural Regen. Res. \n                           12, 72\u201374 (2017).","journal-title":"Neural Regen. Res."},{"key":"23_CR279","first-page":"3713","volume":"17","author":"Y Xu","year":"1997","unstructured":"Xu, Y. et al. The apurinic\/apyrimidinic endonuclease (APE\/ref-1) DNA repair enzyme is elevated in premalignant and malignant cervical cancer. Anticancer Res. \n                           17, 3713\u20133719 (1997).","journal-title":"Anticancer Res."},{"key":"23_CR280","doi-asserted-by":"publisher","first-page":"679","DOI":"10.4161\/cbt.3.7.967","volume":"3","author":"D Wang","year":"2004","unstructured":"Wang, D., Luo, M. & Kelley, M. R. Human apurinic endonuclease 1 (APE1) expression and prognostic significance in osteosarcoma: enhanced sensitivity of osteosarcoma to DNA damaging agents using silencing RNA APE1 expression inhibition. Mol. Cancer Ther. \n                           3, 679\u2013686 (2004).","journal-title":"Mol. Cancer Ther."},{"key":"23_CR281","first-page":"2220","volume":"61","author":"KA Robertson","year":"2001","unstructured":"Robertson, K. A. et al. Altered expression of Ape1\/ref-1 in germ cell tumors and overexpression in NT2 cells confers resistance to bleomycin and radiation. Cancer Res. \n                           61, 2220\u20132225 (2001).","journal-title":"Cancer Res."},{"key":"23_CR282","doi-asserted-by":"publisher","first-page":"6205","DOI":"10.1158\/1078-0432.CCR-05-0045","volume":"11","author":"SC Sak","year":"2005","unstructured":"Sak, S. C., Harnden, P., Johnston, C. F., Paul, A. B. & Kiltie, A. E. APE1 and XRCC1 protein expression levels predict cancer-specific survival following radical radiotherapy in bladder cancer. Clin. Cancer Res. \n                           11, 6205\u20136211 (2005).","journal-title":"Clin. Cancer Res."},{"key":"23_CR283","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/00043426-200105000-00011","volume":"23","author":"B Thomson","year":"2001","unstructured":"Thomson, B., Tritt, R., Davis, M. & Kelley, M. R. Histology-specific expression of a DNA repair protein in pediatric Rhabdomyosarcomas. Am. J. Pediatr. Hematol. Oncol. \n                           23, 234\u2013239 (2001).","journal-title":"Am. J. Pediatr. Hematol. Oncol."},{"key":"23_CR284","first-page":"3510","volume":"7","author":"MS Bobola","year":"2001","unstructured":"Bobola, M. S., Blank, A., Berger, M. S., Stevens, B. A. & Silber, J. R. Apurinic\/apyrimidinic endonuclease activity is elevated in human adult gliomas. Clin. Cancer Res. \n                           7, 3510\u20133518 (2001).","journal-title":"Clin. Cancer Res."},{"key":"23_CR285","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3816\/CLML.2010.n.072","volume":"10","author":"JY Xie","year":"2010","unstructured":"Xie, J. Y. et al. Elevated expression of APE1\/Ref-1 and its regulation on IL-6 and IL-8 in bone marrow stromal cells of multiple Myeloma. Clin. Lymphoma Myeloma Leuk. \n                           10, 385\u2013393 (2010).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"23_CR286","doi-asserted-by":"crossref","unstructured":"Hong, J. et al. APE1-mediated DNA damage repair provides survival advantage for esophageal adenocarcinoma cells in response to acidic bile salts. Oncotarget (2016).","DOI":"10.18632\/oncotarget.7696"},{"key":"23_CR287","doi-asserted-by":"publisher","first-page":"5787","DOI":"10.1021\/acs.biochem.5b00928","volume":"54","author":"E Coskun","year":"2015","unstructured":"Coskun, E., Jaruga, P., Reddy, P. T. & Dizdaroglu, M. Extreme expression of DNA repair protein apurinic\/apyrimidinic endonuclease 1 (APE1) in human breast cancer as measured by liquid chromatography and isotope dilution tandem mass spectrometry. Biochemistry \n                           54, 5787\u20135790 (2015).","journal-title":"Biochemistry"},{"key":"23_CR288","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1002\/ijc.25900","volume":"129","author":"MS Bobola","year":"2011","unstructured":"Bobola, M. S. et al. Apurinic\/apyrimidinic endonuclease is inversely associated with response to radiotherapy in pediatric ependymoma. Int. J. Cancer \n                           129, 2370\u20139 (2011).","journal-title":"Int. J. Cancer"},{"key":"23_CR289","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1111\/j.1349-7006.2012.02239.x","volume":"103","author":"MX Li","year":"2012","unstructured":"Li, M. X. et al. Human apurinic\/apyrimidinic endonuclease 1 translocalizes to mitochondria after photodynamic therapy and protects cells from apoptosis. Cancer Sci. \n                           103, 882\u2013888 (2012).","journal-title":"Cancer Sci."}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-017-0023-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-017-0023-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-017-0023-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,24]],"date-time":"2022-12-24T02:03:10Z","timestamp":1671847390000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-017-0023-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,8]]},"references-count":289,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["23"],"URL":"https:\/\/doi.org\/10.1038\/s41698-017-0023-0","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,8]]},"assertion":[{"value":"7 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Mark R. Kelley has licensed E3330 (APX3330) through Indiana University Research and Technology Corporation to Apexian Pharmaceuticals. Apexian Pharmaceuticals had neither control nor oversight of the studies or the study design, results or interpretation, or presentation of the data in this manuscript. They did not have to approve the manuscript in any way prior to its submission. The other authors declare that they have no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19"}}